Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India



In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 **AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page XXX.

Release date: December 19, 2022; Expiration date: December 19, 2023

Learning Objectives

Upon completion of this activity, participants will be able to:

- Assess risk factors for COVID-19–associated mucormycosis (CAM), including potential associations of COVID-19
 treatment practices with the occurrence of CAM, based on a nationwide case-control study across 25 hospitals in
 India from January to June 2021
- Determine the clinical outcomes of CAM and factors associated with mortality in CAM at 12 weeks, based on a
 nationwide case-control study across 25 hospitals in India from January to June 2021
- Evaluate the clinical implications of risk factors for and clinical outcomes of CAM, including potential associations of COVID-19 treatment practices with the occurrence of CAM, and factors associated with mortality in CAM at 12 weeks, based on a nationwide case-control study across 25 hospitals in India from January to June 2021

CME Editor

Jill Russell, BA, Technical Writer/Editor, Emerging Infectious Diseases. *Disclosure: Jill Russell, BA, has disclosed no relevant financial relationships.*

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has the following relevant financial relationships: formerly owned stocks in AbbVie Inc.

Authors

Valliappan Muthu, DM; Ritesh Agarwal, DM; Shivaprakash Mandya Rudramurthy, MD; Deepak Thangaraju, MD; Manoj Radhakishan Shevkani, MD; Atul K. Patel, MD; Prakash Srinivas Shastri, MD; Ashwini Tayade, MD, DNB, FNB; Sudhir Bhandari, MD; Vishwanath Gella, DM; Jayanthi Savio, MD; Surabhi Madan, MD; Vinay Kumar Hallur, MD; Venkata Nagarjuna Maturu, DM; Arjun Srinivasan, DM; Nandini Sethuraman, MD; Raminder Pal Singh Sibia, MD; Sanjay Pujari, MD; Ravindra Mehta, MD; Tanu Singhal, MD; Puneet Saxena, DM; Varsha Gupta, MD; Vasant Nagvekar, MD; Parikshit Prayag, MD; Dharmesh Patel, MD; Immaculata Xess, MD; Pratik Savaj, DNB; Naresh Panda, MS; Gayathri Devi Rajagopal, MD; Riya Sandeep Parwani, B Pharm; Kamlesh Patel, MD; Anuradha Deshmukh, MD; Aruna Vyas, MD; Srinivas Kishore Sistla, MS; Priyadarshini A. Padaki, MD; Dharshni Ramar, MD; Saurav Sarkar, MS; Bharani Rachagulla, MD; Pattabhiraman Vallandaramam, MD; Krishna Prabha Premachandran, MD; Sunil Pawar, MD; Piyush Gugale, DNB; Pradeep Hosamani, MS; Sunil Narayan Dutt, MS; Satish Nair, MS; Hariprasad Kalpakkam, DM; Sanjiv Badhwar, MS; Kiran Kumar Kompella, MD; Nidhi Singla, MD; Milind Navlakhe, MS; Amrita Prayag, MS; Gagandeep Singh, MD; Poorvesh Dhakecha, MD; and Arunaloke Chakrabarti, MD. Valliappan Muthu, Ritesh Agarwal,¹ Shivaprakash Mandya Rudramurthy, Deepak Thangaraju, Manoj Radhakishan Shevkani, Atul K. Patel, Prakash Srinivas Shastri, Ashwini Tayade, Sudhir Bhandari, Vishwanath Gella, Jayanthi Savio, Surabhi Madan, Vinay Kumar Hallur, Venkata Nagarjuna Maturu, Arjun Srinivasan, Nandini Sethuraman, Raminder Pal Singh Sibia, Sanjay Pujari, Ravindra Mehta, Tanu Singhal, Puneet Saxena, Varsha Gupta, Vasant Nagvekar, Parikshit Prayag, Dharmesh Patel, Immaculata Xess, Pratik Savaj, Naresh Panda, Gayathri Devi Rajagopal, Riya Sandeep Parwani, Kamlesh Patel, Anuradha Deshmukh, Aruna Vyas, Srinivas Kishore Sistla, Priyadarshini A Padaki, Dharshni Ramar, Saurav Sarkar, Bharani Rachagulla, Pattabhiraman Vallandaramam, Krishna Prabha Premachandran, Sunil Pawar, Piyush Gugale, Pradeep Hosamani, Sunil Narayan Dutt, Satish Nair, Hariprasad Kalpakkam, Sanjiv Badhwar, Kiran Kumar Kompella, Nidhi Singla, Milind Navlakhe, Amrita Prayag, Gagandeep Singh, Poorvesh Dhakecha, Arunaloke Chakrabarti¹

We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated with CAM. We included 1,733 cases of CAM and 3,911 age-matched COVID-19 controls. We found cumulative glucocorticoid dose (odds ratio [OR] 1.006, 95% CI 1.004–1.007) and zinc supplementation (OR

Mucormycosis is an invasive fungal infection associated with high death rates. Poorly controlled diabetes mellitus, organ transplantation, hematological malignancies, and immunosuppression are the known predisposing factors for mucormycosis (1). During the second wave of the COVID-19 pandemic (April–June 2021), a large number of cases of COVID-19–associated mucormycosis (CAM) were reported globally, primarily in India (2–5). The explanation for this outbreak of

Author affiliations: Postgraduate Institute of Medical Education and Research, Chandigarh, India (V. Muthu, R. Agarwal, S.M. Rudramurthy, N. Panda, A. Chakrabarti); Kovai Medical Center and Hospital, Coimbatore, India (D. Thangaraju, G.D. Rajagopal); Avron Hospitals, Ahmedabad, India (M.R. Shevkani, R.S. Parwani); Sterling Hospital, Ahmedabad (A.K. Patel, K. Patel); Sir Gangaram Hospital, New Delhi, India (P.S. Shastri); Kingsway Hospital, Nagpur, India (A. Tayade, A. Deshmukh); Sawai Man Singh Medical College, Jaipur, India (S. Bhandari, A. Vyas); Asian Institute of Gastroenterology, Hyderabad, India (V. Gella, S.K. Sistla); St. John's Medical College and Hospital, Bengaluru, India (J. Savio, P.A. Padaki); Care Institute of Medical Sciences, Ahmedabad (S. Madan, D. Ramar); All India Institute of Medical Science Bhubaneswar, Odisha, India (V.K. Hallur, S. Sarkar); Yashoda Hospitals, Hyderabad (V.N. Maturu, B. Rachagulla); Royal Care Hospital, Coimbatore (A. Srinivasan, P. Vallandaramam); Apollo Hospitals, Chennai, India (N. Sethuraman, K.P. Premachandran);

2.76, 95% CI 2.24–3.40), along with elevated C-reactive protein (OR 1.004, 95% CI 1.002–1.006), host factors (renal transplantation [OR 7.58, 95% CI 3.31–17.40], diabetes mellitus [OR 6.72, 95% CI 5.45–8.28], diabetic ketoacidosis during COVID-19 [OR 4.41, 95% CI 2.03–9.60]), and rural residence (OR 2.88, 95% CI 2.12–3.79), significantly associated with CAM. Mortality rate at 12 weeks was 32.2% (473/1,471). We emphasize the judicious use of COVID-19 therapies and optimal glycemic control to prevent CAM.

CAM in India remains unclear. Diabetes mellitus and glucocorticoids (used for treating COVID-19) have been identified as risk factors for CAM (2,6). Other factors proposed in the pathogenesis of CAM include altered iron metabolism, the severity of COVID-19, and immune dysfunction resulting from COVID-19 (e.g., lymphopenia and others) (7,8).

A high burden of Mucorales (in the hospital and outdoor environments) has been reported in India

Government Medical College, Patiala, India (R.P.S. Sibia,
S. Pawar); Poona Hospital and Research Centre, Pune, India
(S. Pujari, P. Gugale); Apollo Hospitals, Bengaluru (R. Mehta,
H. Kalpakkam, P. Hosamani, S.N. Dutt, S. Nair); Kokilaben
Dhirubhai Ambani Hospital and Medical Research Institute,
Mumbai, India (T. Singhal, S. Badhwar); Army Hospital (Research and Referral), New Delhi (P. Saxena, K.K. Kompella); Government
Medical College, Chandigarh (V. Gupta, N. Singla); Global Hospital,
Mumbai (V. Nagvekar, M. Navlakhe); Deenanath Mangeshkar
Hospital, Pune (P. Prayag, A. Prayag); City Clinic and Bhailal Amin
General Hospital, Vadodara, India (D. Patel); All India Institute
of Medical Sciences, New Delhi (I. Xess, G. Singh); Institute of
Infectious Disease and Critical Care Hospital, Surat, India (P. Savaj,
P. Dhakecha)

DOI: https://doi.org/10.3201/eid2901.220926

¹These senior authors contributed equally to this article..

during and even before the CAM epidemic (9,10). We also found no difference in the Mucorales species causing mucormycosis before and during the CO-VID-19 pandemic (2,11). The epidemiologic triad of agent, environmental, and host factors is helpful to explain the occurrence of a new illness or the recrudescence of an old disease (6,8,9). Because the data indicate no change in the environment or the agent (Mucorales), we hypothesized that COVID-19, its treatment, and specific host factors contributed to the CAM outbreak.

We evaluated the risk factors and clinical outcomes of CAM in a nationwide study. The main objective of our study was to assess whether treatment practices in COVID-19 were associated with the occurrence of CAM. We also evaluate the factors associated with death from CAM at 12 weeks.

Methods

Study Design and Setting

We performed a multicenter (25 centers across India) case-control study during January 1-June 30, 2021 (Appendix Figure, https://wwwnc.cdc.gov/EID/article/29/1/22-0926-App1.pdf). We included CAM patients (cases) and at least 2 COVID-19 patients without mucormycosis (controls) for each case. Only those centers willing to provide data on \geq 15 cases of mucormycosis during the outbreak were included (Appendix Table 1).

The Institute Ethics Committees approved the study protocol at the individual study sites. A consent waiver was granted because we used anonymized patient data for analysis. The study is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (Appendix) (12).

Cases and Controls

We confirmed COVID-19 diagnosis by SARS-CoV-2 RNA positivity in respiratory specimens by reverse transcription PCR or a positive rapid antigen test. We included only confirmed (proven and probable) cases of mucormycosis diagnosed and managed at the individual centers (13). Participating centers were tertiary care referral hospitals or research institutes equipped with the facilities required to evaluate and manage mucormycosis. We evaluated patient samples at the study sites by conventional microscopy (KOH-calcofluor method), culture, histopathology, or molecular diagnostic techniques, as appropriate. We identified positive cultures on the basis of macroscopic and microscopic characteristics of the growth or by sequencing of the internal transcribed spacer region of rDNA. We subjected tissue samples for histopathological examination and used hematoxylin and eosin, periodic acid Schiff, or Gomori's methenamine silver stain. We diagnosed invasive mucormycosis on the basis of existing guidelines and as previously described (11,13). In brief, we categorized participants' illness as proven mucormycosis if Mucorales were isolated or broad ribbon-like aseptate hyphae were demonstrated from sterile sites or deep tissue biopsy. We defined probable mucormycosis in the presence of host risk factors, consistent imaging (e.g., reversed halo sign, thick-walled cavity, and others on computed tomography), and the demonstration of Mucorales by either microscopy or culture from a nonsterile site (sputum, nasal smear, or bronchoalveolar lavage fluid) (13,14). We defined disseminated mucormycosis as >1 noncontiguous site being involved. We excluded cases without microbiological or pathological confirmation of mucormycosis. We considered isolation of Mucorales from respiratory secretions without compatible host factors, clinical features, or radiology as colonization, and these cases were not included. We further classified CAM as concurrent (occurrence of mucormycosis within 7 days before or after diagnosing COVID-19) or nonconcurrent (after 7 days but within 3 months of COVID-19 diagnosis).

We enrolled ≥ 2 age-matched (± 5 years) persons with confirmed COVID-19 as controls for each CAM case. The controls were selected randomly by the individual centers. We also reviewed patient records or contacted control-patients by telephone 3 months after COVID-19 diagnosis to ensure CAM had not developed.

Patients were managed per the local institutional protocol and the treating physician's discretion. Mucormycosis was treated according to the standard recommendations, subject to the availability of drugs and other factors (1,15). We recorded the first antifungal medication (amphotericin B, posaconazole, isavuconazole, or a combination) used for managing mucormycosis and whether lack of availability of the intended drug led to the use of an alternate agent. We defined the use of \geq 2 antifungal agents effective against Mucorales within the first 14 days of CAM as primary combination antifungal therapy. We also noted whether \geq 1 doses were missed because of drug unavailability.

Exposures and Confounding Variables

The primary exposure variable was the type of treatment offered for COVID-19. The therapies consisted of glucocorticoids, remdesivir, tocilizumab, baricitinib zinc supplements, antibacterial agents, and antifungal therapy (before onset of mucormycosis). We defined inappropriate glucocorticoid therapy as use of systemic glucocorticoids for COVID-19 without related hypoxemia. We recorded information on the dose and duration of glucocorticoids used for COVID-19 and calculated the cumulative dose of glucocorticoids by multiplying the number of days of therapy and the dose used (dexamethasone equivalent).

We accounted for potential confounding variables pertaining to CAM by retrieving demographic and clinical information about COVID-19 illness from patient records. That information was sex; place of residence (rural or urban); investigations performed during admission (the first available values) for acute COVID-19 illness, including glycated hemoglobin (HbA1C), plasma glucose, complete blood count, serum ferritin, C-reactive protein, and neutrophilto-lymphocyte ratio; host factors, including diabetes mellitus (labeled as recent-onset if diagnosed during the current admission and there was no previous history of diabetes), diabetic ketoacidosis during admission for COVID-19, hematological malignancy, stem cell or organ transplantation, and immunosuppressive therapy (for indications unrelated to COVID-19); chronic comorbidities (chronic liver, kidney, lung, and other diseases); hypoxemia during acute COV-ID-19 (<94% oxygen saturation while breathing ambient air or requiring supplemental oxygen); and the need for mechanical ventilation.

We also evaluated factors associated with 12week mortality in CAM patients. We collected the following data: time to diagnosis of mucormycosis after confirmed COVID-19, diagnosis of mucormycosis (microscopy, culture, histopathology), anatomic site of involvement (rhino-orbital mucormycosis, pulmonary, or others), treatment details (antifungal therapy, surgery, and others), and outcome at 6 and 12 weeks.

Study Size

We assumed the primary exposure of interest (treatment practices, primarily glucocorticoids) would be present in 60% of controls and 70% of cases. The estimated sample size was 374 cases and 747 controls for a case: control enrollment ratio of 1:2, at a power of 90% for detecting 1.25 odds (in cases than controls). We planned a convenient sample size by enrolling \geq 15 consecutive CAM cases from each participating center.

Statistical Analysis

We analyzed data by using the commercial statistical package SPSS Statistics 22.0 (IBM, https://www.ibm. com). As appropriate, descriptive data are presented

as frequencies, means and SDs, or medians and interquartile ranges. We compared categorical variables by using the χ^2 test or Fisher exact test and analyzed the differences between continuous data by using the Student *t*-test or Mann-Whitney U test, as appropriate. We considered a p value <0.05 significant.

We imputed the missing data for performing the subsequent logistic regression analysis. The pattern of missing data (missing at random or not) was ascertained. We then performed multiple imputations (50 iterations) by using the Markov Chain Monte Carlo method (Appendix Table 2). We performed multivariate logistic regression analyses to identify the factors associated with the development of CAM (vs. COV-ID-19 controls) and ascertain factors associated with 12-week mortality in persons with CAM. The variables included in the logistic regression model were decided on the basis of the univariate analysis and biologic plausibility. The strength of association was reported as an adjusted odds ratio (aOR) with 95% CI. To elucidate the confounding resulting from the difference in severity among the controls and cases, we repeated the multivariate analysis in the following subgroups: nonhypoxemic versus hypoxemic COVID-19 control-patients and COVID-19 controlpatients with and without comorbidities. We also report the sensitivity analysis on the available data (complete case analysis) for the logistic regression.

Results

We included 1,733 CAM case-patients and 3,911 control-patients in the study (Table 1). Of the study participants, 684 did not require hospitalization for the management of acute COVID-19.

Exposure

Glucocorticoids were used for COVID-19 in 71.6% (3,890/5,431) patients (cumulative dose range 0.76-679.53 mg dexamethasone equivalent), and their use was more frequent in CAM case-patients. The median dose and duration of glucocorticoid use was also higher in case-patients than control-patients (Table 1). The proportion of persons receiving glucocorticoids in the absence of hypoxemia (inappropriate use) was even higher in CAM patients (34.2% vs. 22.3%; p = 0.0001) than control-patients. In addition, the percentage of persons receiving more than the recommended dose (>60 mg of dexamethasone or equivalent) of glucocorticoids was higher among CAM casepatients than COVID-19 control-patients (Figure), both for hypoxemic (269/439 [61.3%] vs. 683/1389 [49.2%]; p = 0.0001 and nonhypoxemic (124/329)[37.7%] vs. 143/633 [22.6%]; p = 0.0001) persons. Zinc

supplementation during COVID-19 illness was higher among case-patients than controls (47.9% vs. 41.3%; p = 0.0001). Remdesivir (49.2% vs. 20.6%; p = 0.0001) and antibacterial therapy (64.2% vs. 61.1%; p = 0.03) were more commonly used in controls. No difference was noted in the proportion of participants receiving tocilizumab, baricitinib, or antifungal therapy before the development of CAM.

Julie 2021 Controls, n = 3,911 CAM, n = 1,733 p value Age, y, mean (SD) 52.7 (13.5) 52.6 (12.5) 0.68 Male sex 2,7363,011 (70.0) 1,285/r,733 (74.1) 0.0001 Rural residence, n = 3,924 3092,615 (11.8) 360/1,733 (18.2) 0.0001 None 1,743,3911 (43.5) 1,3741,733 (18.2) 0.0001 None 1,743,3911 (45.1) 1,4021,733 (80.9) 0.0001 Plastin Stoter 923,911 (53.1) 1,4021,733 (80.9) 0.0001 Plasting optiential risk factors for mucormycosis† 1,763/3,911 (45.1) 1,4021,733 (80.9) 0.0001 Plasting optiential risk factors 923,911 (24.9) 430,753 (25.1) 1,012,1733 (80.9) 0.0001 Diates ext domission, n = 5,236 9980,252 (27.5) 10.1 (2.9) 0.0001 Diatration of diabetes y, mean (SD), n = 1,556 7.7 (2.5) 10.1 (2.9) 0.0001 Diatration of diabetes willius 3191,763 (18.1) 246/1,402 (17.5) 0.68 DKA at the time of admission for COVID-19 480,763 (2.7) 731,402 (5.2) 0.0001 Dimostophy ext transplant	Table 1. Baseline features of CAM case-patients and COVID-19 cor	ntrol-patients at admission fo	or COVID-19, India, January	-
Catagory Controls		Controls $p = 3.011$	CAM = 1.733	n valuo
Page 9, interact (SD) D2.0 (12.3) D3.0 (12.3) D3.0 (12.3) Rural residence, n = 3.924 309/2,615 (11.8) 300/1,309 (27.5) 0.0001 None 2,076/3,911 (53.1) 316/1,733 (18.2) 0.0001 None 1,734/3,911 (44.5) 1,734/1,733 (79.3) 21 >1 risk factor 92/3,911 (2.4) 43/1,733 (2.5) 0.0001 Details of potential risk factors for mucormycosis† 1,763/3,911 (45.1) 1,402/1,733 (80.9) 0.0001 Plasma glucose at admission, n = 5,236 998/3,625 (27.5) 758/1,611 (47.1) 0.0001 Diatetes mellitus 1,96 (9.5) 8.4 (6.8) 0.0001 Duration of diabetes, y, mean (SD), n = 861 9.6 (9.5) 8.4 (6.8) 0.0001 Duration of diabetes, y, mean (SD), n = 861 9.6 (9.5) 8.4 (6.8) 0.0005 Bena transplant 36/3,911 (0.9) 311/1,733 (1.8) 0.005 Bena transplant 36/3,911 (0.9) 311/1,733 (1.8) 0.005 Borne marrow transplant 0/3,911 (0.9) 61/1,733 (0.3) 0.022 Immunosuppressive therapy 76/3,911 (1.9) 22/1,733 (1.3)	Age v meen (SD)	52 7 (12 5)	E2.6 (12.5)	
Inde Sex 2/100/2011 (100) 1/2001 (101) 0.0001 Risk factors for mucomycosis 0.0001 0.0001 None 2.076/3.911 (53.1) 316/1.733 (18.2) 0.0001 1 risk factor 1.743/3.911 (44.5) 1.374/1.733 (26.5) 0.0001 Date tes mellius 1.763/3.911 (45.1) 1.402/1.733 (26.5) 0.0001 Hyperglycemia at admission, m. = 5,236 998/3.622 (27.5) 758/1.611 (47.1) 0.0001 Hyperglycemia at admission, m. = 5,236 7.7 (2.5) 10.1 (2.9) 0.0001 Cycated hemoglobin, mean (SD), n = 1.856 7.7 (2.5) 10.1 (2.9) 0.0001 Duration of diabetes, viewan (SD), n = 861 9.6 (9.5) 8.4 (6.8) 0.04 Recent onset of diabetes mellitus 319/1.763 (18.1) 240/1.402 (17.5) 0.66 DKA at the time of admission for COVID-19 48/1.763 (2.7) 73/1.402 (17.5) 0.60 Immunosuppressive therapy 76/3.911 (0.9) 31/1.733 (0.3) 0.02 Immunosuppressive therapy 76/3.911 (1.7) 22/1.733 (0.3) 0.23 Comorbidities 26/1.733 (1.3) 0.0001 22/1.73	Age, y, mean (SD)	2 738/3 011 (70 0)	1 285/1 722 (7/ 1)	0.00
$\begin{array}{c} \text{None} \\ \text{Risk factors for mucomycosis} \\ \text{None} \\ 1 \text{ risk factors} \\ 1 risk f$	$\frac{1}{2}$	2,730/3,911 (70.0)	260/1 200 (27 5)	0.002
None 2.076/3.911 (53.1) 316/1.733 (18.2) 0.0001 1 risk factor 1.743/3.911 (44.5) 1.374/1.733 (79.3) 2 2 ri risk factor 92/3.911 (24.4) 43/1.733 (2.5) 0.0001 Hyperglycemia at admission, m = 5.236 998/3.625 (27.5) 758/1.611 (47.1) 0.0001 Hyperglycemia at admission, mean (SD), n = 3.487 195 (94) 235 (106) 0.0001 Glycated hemoglobin, mean (SD), n = 861 9.6 (9.5) 8.4 (6.8) 0.04 Recent onset of diabetes, wean (SD), n = 861 9.6 (9.5) 8.4 (6.8) 0.0005 Bone marrow transplant 073.911 (0.9) 1/1.733 (1.8) 0.005 Bone marrow transplant 03.911 (0.9) 6/1.733 (0.3) 0.23 Immunosuppressive therapy 763.911 (1.9) 22/1.733 (1.3) 0.07 Hirk 243.911 (2.5) 265/1.733 (1.5.3) 0.0001 Cornorbidities 2/3.911 (0.2) 6/1.733 (0.3) 0.23 Comorbidities 2/3.911 (1.9) 2/1.733 (1.0) 0.21 Any comorbidity 2/3.911 (1.5) 17/1.733 (1.0) 0.0001	Rulai residence, n = 3,924	309/2,013 (11.8)	300/1,309 (27.3)	0.0001
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	None	2 076/3 011 (53 1)	316/1 733 (18 2)	0.0001
11 instruction 1,140,311 (H3,3) 1,214,143 (14,3) 2+1 risk factors 92/3,911 (42,1) 43/1,733 (2,5) Details of potential risk factors for mucormycosis† 1,763/3,911 (45,1) 1,402/1,733 (0,5) Diabetes mellitus 1,763/3,911 (45,1) 1,402/1,733 (0,5) 0,0001 Hyperglycemia at admission, m = 5,236 998/3,625 (27,5) 10,1 (2,9) 0,0001 Glycated hemoglobin, mean (SD), n = 1,856 7,7 (2,5) 10,1 (2,9) 0,0001 Duration of diabetes, wean (SD), n = 861 36 (9,5) 8.4 (6,8) 0,04 Recent onset of diabetes mellitus 3191,763 (18,1) 246/1,402 (17,5) 0,66 DKA at the time of admission for COVID-19 48/1,763 (2,7) 73/1,402 (5,2) 0,0003 Bene marrow transplant 0/3,911 (0,9) 61/1,733 (0,3) 0,02 11,733 (0,3) 0,02 Immunosuppressive therapy 76/3,911 (0,9) 61/1,733 (0,3) 0,02 11,733 (0,3) 0,02 Comorbidities 2/2,911 (0,0) 2/1,733 (0,3) 0,02 11,733 (0,1) 0,23 Any comorbidity 828/3,911 (2,5) 97/1,733 (1,3) 0,00	1 risk factor	1 7/3/3 011 (// 5)	1 374/1 733 (70 3)	
Definition Definition Definition Definition Definition Diabates mellitus 1,7633,911 (45.1) 1,402/1,733 (80.9) 0,0001 Plasma glucose at admission, n = 5,236 9993,622 (27.5) 758/1,611 (47.1) 0,0001 Plasma glucose at admission, n = 1,856 9.6 (9.5) 8.4 (6.8) 0.040 Duration of diabetes, y, mean (SD), n = 861 9.6 (9.5) 8.4 (6.8) 0.04 Recent noset of diabetes mellitus 319/1,763 (8.1) 246/1,402 (17.5) 0.6003 Breal transplant 063,911 (0.9) 31/1,733 (1.8) 0.0001 Humosuppressive therapy 763,911 (0.9) 6/1,733 (0.3) 0.02 Immunosuppressive therapy 763,911 (0.9) 21/1,733 (1.3) 0.07 HIV 7/3,911 (0.0) 21/1,733 (1.0) 0.23 Comorbiditity 828/3,911 (2.5) 265/1,733 (0.5) 0.0001 Corronary artery disease 24/3,911 (7.3) 98/1,733 (0.5) 0.0001 Chronic kindery disease 71/3,911 (1.8) 13/1,733 (1.6) 0.11 Chronic kindery disease 12/2 (2.4) 12.1 (2.2)	>1 risk factors	92/3 911 (2 4)	A3/1 733 (2 5)	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Details of potential risk factors for mucormycosist	52/5,511 (2.4)	46/1,766 (2.5)	
Hyperglycemia at admission, n = 5,236 1098/3,225 (27.5) 758/1,611 (4(1.1) 0.0001 Plasma glucose at admission, mg/dL, mean (SD), n = 3,487 195 (94) 235 (106) 0.0001 Glycated hemoglobin, mean (SD), n = 1,856 9.6 (9.5) 8.4 (6.8) 0.0001 Duration of diabetes, y, mean (SD), n = 861 9.6 (9.5) 8.4 (6.8) 0.0001 Recent noset of diabetes mellitus 3191/7,63 (2.1) 246/1,402 (5.2) 0.0003 Bon mearcow transplant 0/3,911 (0.9) 31/1,733 (0.1) 0.31 Hematological malignancy 36/3,911 (0.9) 6/1,733 (0.3) 0.02 Immunosuppressive therapy 7/3,911 (0.9) 21/1,733 (0.1) 0.23 Comorbidities 2/2,311 (0.0) 21/1,733 (1.3) 0.07 HIV 7/3,911 (2.1) 266/1,733 (1.5.) 0.0001 Comorbidities 2/2,311 (0.0) 21/1,733 (0.1) 0.23 Comorbidities 2/2,311 (1.5) 17/1,733 (1.0) 0.11 Chronic kidney disease 2/8/3,911 (2.1) 266/1,733 (1.5.) 0.0001 Chronic kidney disease 1/3,3911 (1.2) 17/1,733 (0.0) <td>Diabetes mellitus</td> <td>1 763/3 911 (45 1)</td> <td>1 402/1 733 (80 9)</td> <td>0.0001</td>	Diabetes mellitus	1 763/3 911 (45 1)	1 402/1 733 (80 9)	0.0001
Plasma glucose at admission, mg/dL, mean (SD), n = 3.487 195 (94) 235 (106) 0.0001 Glycated hemoglobin, mean (SD), n = 1.856 7, 7 (2.5) 10.1 (2.9) 0.0001 Duration of diabetes, ymean (SD), n = 861 9.6 (9.5) 8.4 (6.8) 0.04 Recent onset of diabetes mellitus 3191,763 (18.1) 2461,402 (17.5) 0.66 DKA at the time of admission for COVID-19 481,763 (2.7) 731,402 (5.2) 0.0003 Renal transplant 0/3,911 (0.9) 31/1,733 (1.8) 0.005 Bone marrow transplant 0/3,911 (0.9) 61/1,733 (0.3) 0.23 Cherst_ 2/3,911 (0.0) 21/1,733 (1.3) 0.07 HIV 7/3,911 (0.2) 61/1,733 (0.3) 0.23 Comorbidities 2/3,911 (1.5) 265/1,733 (1.5.3) 0.0001 Any comorbidity 828/3,911 (2.1,5) 265/1,733 (0.5.3) 0.0021 Chronic kidney disease 28/3,911 (1.5) 71/1,733 (0.8) 0.0021 Chronic kidney disease 71/3,911 (1.5) 71/1,733 (0.8) 0.0021 Chronic kidney disease 71/3,911 (1.5) 71/1,733 (0.8) <	Hyperglycemia at admission $n = 5,236$	998/3 625 (27 5)	758/1 611 (47 1)	0.0001
Glycated hemoglobin, mean (SD), n = 1,856 7.7 (2.5) 10.1 (2.9) 0.0001 Duration of diabetes, y, mean (SD), n = 861 9.6 (9.5) 8.4 (6.8) 0.04 Recent noset of diabetes mellius 3191/753 (18.1) 246/1.402 (17.5) 0.66 DKA at the time of admission for COVID-19 48/1.763 (2.7) 73/1.402 (5.2) 0.0003 Bone marrow transplant 0/3.911 (0.9) 11/1.733 (1.8) 0.005 Bone marrow transplant 0/3.911 (0.9) 6/1.733 (0.3) 0.023 Immunosuppressive therapy 76/3.911 (0.9) 2/1.733 (0.3) 0.23 Otherst 2/3.911 (0.0) 2/1.733 (0.1) 0.23 Comorbidities 2/3.911 (2.5) 265/1.733 (1.5.3) 0.0001 Coronary artery disease 284/3.911 (2.15) 265/1.733 (1.5.3) 0.0021 Chronic kidney disease 284/3.911 (1.8) 3/1.733 (0.0) 0.11 Chronic kidney disease 284/3.911 (2.7) 17/1.733 (1.0) 0.011 Chronic kidney disease 71/3.911 (1.8) 3/1.733 (0.0) 0.021 Chronic kidney disease 71/3.911 (1.8) 3/1.733 (0.0)	Plasma glucose at admission $mg/dl mean (SD) n = 3.487$	195 (94)	235 (106)	0.0001
	Glycated hemoglobin mean (SD) $n = 1.856$	77(25)	10 1 (2 9)	0.0001
Recent onset of diabetes mellitus $319/1,763$ (18.1) $246/1,402$ (17.5) 0.66 DKA at the time of admission for COVID-19 $481/1,763$ (2.7) $731/1,402$ (5.2) 0.0003 Bone marrow transplant $0/3,911$ (0.9) $311/7,33$ (1.8) 0.005 Bone marrow transplant $0/3,911$ (0.9) $61/7,33$ (0.3) 0.02 Immunosuppressive therapy $76/3,911$ (1.9) $221/7,33$ (1.3) 0.07 HIV $73,911$ (0.2) $61/7,33$ (0.3) 0.23 Otherst $23,911$ (0.0) $21/7,33$ (0.1) 0.23 Comorbidities $23,911$ (2.5) $266/7,733$ (1.5) 0.98 Chronic kidney disease $284/3,911$ (2.5) $266/7,733$ (1.5) 0.0001 Chronic kidney disease $284/3,911$ (2.7) $71/7,33$ (1.0) 0.11 Chronic kidney disease $71/3,911$ (1.8) $13/7,733$ (1.0) 0.0001 Dthersty $153/3,911$ (2.7) $71/7,733$ (1.0) 0.0001 Chronic kidney disease $71/3,911$ (1.8) $13/7,733$ (0.0) 0.0001 Laboratory parameters	Duration of diabetes, v. mean (SD), $n = 861$	9.6 (9.5)	8.4 (6.8)	0.04
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Recent onset of diabetes mellitus	319/1.763 (18.1)	246/1.402 (17.5)	0.66
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	DKA at the time of admission for COVID-19	48/1,763 (2.7)	73/1,402 (5.2)	0.0003
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Renal transplant	36/3,911 (0.9)	31/1,733 (1.8)	0.005
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Bone marrow transplant	0/3,911 (0)	1/1,733 (0.1)	0.31
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Hematological malignancy	36/3,911 (0.9)	6/1,733 (0.3)	0.02
HIV 7/3,911 (0.2) 6/1,733 (0.3) 0.23 Others‡ 2/3,911 (0.0) 2/1,733 (0.1) 0.23 Comorbidities 828/3,911 (21.5) 265/1,733 (15.3) 0.0001 Coronary artery disease 284/3,911 (7.3) 126/1,733 (7.3) 0.98 Chronic kidney disease 284/3,911 (7.3) 98/1,733 (5.7) 0.03 Chronic kidney disease 284/3,911 (1.5) 17/1,733 (1.0) 0.011 Chronic kidney disease 71/3,911 (1.5) 17/1,733 (1.0) 0.001 Others§ 151/3,911 (2.7) 17/1,733 (1.0) 0.0001 Others§ 151/3,911 (3.9) 35/1,733 (2.0) 0.0001 Unters§ 151/3,911 (3.9) 35/1,733 (2.0) 0.0001 Median absolute lymphocyte count, cells/µL (lQR), n = 4,129 1,135 (720–1,706) 1,275 (803–1,833) 0.0001 Median absolute lymphocyte count, cells/µL (lQR), n = 4,071 6,177 (3,658–10,244) 7,858 (4,943–11,867) 0.0001 Median absolute reutrophil count, cells/µL (lQR), n = 4,071 6,177 (3,658–10,244) 7,858 (4,943–11,867) 0.0001 Median C-reactive protein mg/dL (IQR), n = 3,972	Immunosuppressive therapy	76/3,911 (1.9)	22/1,733 (1.3)	0.07
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	HIV	7/3,911 (0.2)	6/1,733 (0.3)	0.23
$\begin{array}{c c} \hline Comorbidities \\ Any comorbidity \\ Any comorbidity \\ Coronary artery disease \\ (Coronary artery disease \\ (Coronary artery disease \\ (Coronary artery disease \\ (Coronic kidney disease \\ (Coronic heart failure \\ (Coronic respiratory disease \\ (Coronic disease \\ (Coronic respiratory disease \\ (Coronic respiratory disease \\ (Coronic respiratory disease \\ (Coronic respiratory disease \\ (Coronic disease \\ (Coronic respiratory disease \\ (Coronic disease \\ (Coronic respiratory disease \\ (Coronic respirato$	Others‡	2/3,911 (0.0)	2/1,733 (0.1)	0.23
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Comorbidities			
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Any comorbidity	828/3,911 (21.5)	265/1,733 (15.3)	0.0001
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Coronary artery disease	285/3,911 (7.3)	126/1,733 (7.3)	0.98
$\begin{array}{c} \mbox{Chronic heart failure} & 59/3,911 (1.5) & 17/1,733 (1.0) & 0.11 \\ \mbox{Chronic respiratory disease} & 71/3,911 (1.8) & 13/1,733 (0.8) & 0.002 \\ \mbox{Chronic respiratory disease} & 104/3,911 (2.7) & 17/1,733 (1.0) & 0.001 \\ Chronic respiratory parameters during COVID-19 illness \\ \mbox{Hemoglobin, g/dL, mean (SD), n = 4,506 & 12.2 (2.4) & 12.1 (2.2) & 0.11 \\ \mbox{Total leukocyte count, cells/µL, (lQR), n = 4,021 & 9,853 (6,844) & 11,396 (6,110) & 0.0001 \\ \mbox{Median absolute lymphocyte count, cells/µL (lQR), n = 4,021 & 9,853 (6,844) & 11,396 (6,110) & 0.0001 \\ \mbox{Median absolute neutrophil count, cells/µL (lQR), n = 4,071 & 6,177 (3,658 - 10,244) & 7,858 (4,943 - 11,867) & 0.0001 \\ \mbox{Median absolute neutrophil count, cells/µL (lQR), n = 4,071 & 5,5 (2.7 - 11.4) & 5.7 (3.2 - 11.7) & 0.04 \\ \mbox{Platelet count, x 103/µL, mean (SD), n = 4,454 & 222 (107) & 240 (105) & 0.0001 \\ \mbox{Median Serum ferritin, µg/L (lQR), n = 3,972 & 26.7 (8.4 - 79.3) & 48.8 (20 - 102.5) & 0.0001 \\ \mbox{Median serum ferritin, µg/L (lQR) n = 3,168 & 454 (189 - 977) & 580 (238 - 1,052) & 0.02 \\ \mbox{Details of COVID-19 illness & Hypoxemia, n = 5,476 & 2,100/3,851 (54.5) & 751/1,625(46.2) & 0.0001 \\ \mbox{Mechanical ventilation, n = 5,376 & 1,551/3,809 (40.7) & 3311,616 (20.5) & 0.0001 \\ \mbox{Mechanical ventilation, n = 5,471 & 2,690/3,827 (70.3) & 1,200/1,604 (74.8) & 0.001 \\ \mbox{Glucocorticoid use in the absence of hypoxemia, n = 5,021 & 789/3,532 (22.3) & 509/1,489 (34.2) & 0.0001 \\ \mbox{Median no. days on glucocorticoid ireatment (IQR), n = 2,887 & 8 (5-12) & 10 (6.3 - 14) & 0.0001 \\ \mbox{Median no. days on glucocorticoid ireatment (IQR), n = 2,887 & 8 (5-12) & 10 (6.3 - 14) & 0.0001 \\ \mbox{Zinc supplementation, n = 5,179 & 1,502/3,631 (49.2) & 317/1,536 (2.4) & 0.41 \\ \mbox{Zinc supplementation, n = 5,167 & 72/3,631 (2.0) & 37/1,536 (2.4) & 0.41 \\ \mbox{Zinc supplementation, n = 5,167 & 72/3,631 (2.0) & 37/1,536 (2.4) & 0.41 \\ \mbox{Zinc supplementation, n = 5,167 & 72/3,631 (2.0) & 37/1,536 $	Chronic kidney disease	284/3,911 (7.3)	98/1,733 (5.7)	0.03
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Chronic heart failure	59/3,911 (1.5)	17/1,733 (1.0)	0.11
$\begin{array}{c} \mbox{Chronic respiratory disease} & 104/3,911 (2.7) & 17/1,733 (1.0) & 0.001 \\ \hline Others \S & 151/3,911 (3.9) & 35/1,733 (2.0) & 0.001 \\ \hline Laboratory parameters during COVID-19 illness \\ \mbox{Hemoglobin, gidL, mean (SD), n = 4,506 & 12.2 (2.4) & 12.1 (2.2) & 0.11 \\ \hline Total leukocyte count, cells/µL, mean (SD), n = 4,501 & 9,853 (6,844) & 11,396 (6,110) & 0.0001 \\ \mbox{Median absolute heutrophil count, cells/µL (IQR), n = 4,129 & 1,135 (720-1,706) & 1,275 (803-1,833) & 0.0001 \\ \mbox{Median absolute neutrophil count, cells/µL (IQR), n = 4,071 & 6,177 (3,658-10,244) & 5.7 (3.2-11.7) & 0.04 \\ \mbox{Platelet count, \times 10^3/µL, mean (SD), n = 4,454 & 222 (107) & 240 (105) & 0.0001 \\ \mbox{Median Serum ferritin, µg/L (IQR) n = 3,972 & 26.7 (8.4-79.3) & 48.8 (20-102.5) & 0.0001 \\ \mbox{Median serum ferritin, µg/L (IQR) n = 3,168 & 454 (189-977) & 580 (238-1,052) & 0.02 \\ \mbox{Details of COVID-19 illness } & & & & & & & & & & & & & & & & & &$	Chronic liver disease	71/3,911 (1.8)	13/1,733 (0.8)	0.002
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Chronic respiratory disease	104/3,911 (2.7)	17/1,733 (1.0)	0.0001
Laboratory parameters during COVID-19 illnessHemoglobin, g/dL, mean (SD), n = 4,50612.2 (2.4)12.1 (2.2)0.11Total leukocyte count, cells/µL, mean (SD), n = 4,5019,853 (6,844)11,396 (6,110)0.0001Median absolute lymphocyte count, cells/µL (IQR), n = 4,1291,135 (720–1,706)1,275 (803–1,833)0.0001Median absolute neutrophil count, cells/µL (IQR), n = 4,0716,177 (3,658–10,244)7,858 (4,943–11,867)0.0001Median NLR (IQR), n = 4,0615.5 (2.7–11.4)5.7 (3.2–11.7)0.04Platelet count, × 10 ³ /µL, mean (SD), n = 4,454222 (107)240 (105)0.0001Median C-reactive protein mg/dL (IQR), n = 3,97226.7 (8.4–79.3)48.8 (20–102.5)0.002Details of COVID-19 illness454 (189–977)580 (238–1,052)0.02Metian serum ferritin, µg/L (IQR) n = 3,1682,100/3,851 (54.5)751/1,625(46.2)0.0001ICU admission, n = 5,4761,126/3,765 (29.9)153/1,611 (9.5)0.0001Management during COVID-19I1,126/3,765 (29.9)153/1,611 (9.5)0.0001Glucocorticoid use in the absence of hypoxemia, n = 5,021789/3,532 (22.3)509/1,489 (34.2)0.0001Glucocorticoid use of glucocorticoids in milligram52.8 (30–84)62.6 (30.2–120)0.0001equivalent of dexamethasone (IQR), n = 2,8098 (5–12)10 (6.3–14)0.0001Zinc supplementation, n = 5,1791,502/3,633 (41.3)741/1,546 (47.9)0.0001Zinc supplementation, n = 5,16772/3,631 (49.2)317/1,536 (2.4)0.401 <td>Others§</td> <td>151/3,911 (3.9)</td> <td>35/1,733 (2.0)</td> <td>0.0001</td>	Others§	151/3,911 (3.9)	35/1,733 (2.0)	0.0001
Hemoglobin, g/dL, mean (SD), n = 4,50612.2 (2.4)12.1 (2.2)0.11Total leukocyte count, cells/µL, mean (SD), n = 4,5019,853 (6,844)11,396 (6,110)0.0001Median absolute lymphocyte count, cells/µL (IQR), n = 4,1291,135 (720-1,706)1,275 (803-1,833)0.0001Median absolute neutrophil count, cells/µL (IQR), n = 4,0716,177 (3,658-10,244)7,858 (4,943-11,867)0.0001Median nLR (IQR), n = 4,0615.5 (2.7-11.4)5.7 (3.2-11.7)0.04Platelet count, $\times 10^3$ /µL, mean (SD), n = 4,454222 (107)240 (105)0.0001Median serum ferritin, µg/L (IQR) n = 3,168454 (189-977)580 (238-1,052)0.02Details of COVID-19 illness1,263,765 (29.9)153/1,611 (9.5)0.0001Mechanical ventilation, n = 5,4762,100/3,851 (54.5)751/1,625(46.2)0.0001Management during COVID-191,126/3,765 (29.9)153/1,611 (9.5)0.0001Glucocorticoid therapy, n = 5,4312,690/3,827 (70.3)1,200/1,604 (74.8)0.001Glucocorticoid use in the absence of hypoxemia, n = 5,021789/3,532 (22.3)509/1,489 (34.2)0.0001Median no. days on glucocorticoids in milligram52.8 (30-84)62.6 (30.2-120)0.0001Zinc supplementation, n = 5,1791,502/3,633 (41.3)741/1,546 (47.9)0.0001Zinc supplementation, n = 5,1677,785/3,631 (49.2)317/1,536 (2.4)0.41	Laboratory parameters during COVID-19 illness			
Total leukocyte count, cells/µL, mean (SD), n = 4,5019,853 (6,844)11,396 (6,110)0.0001Median absolute lymphocyte count, cells/µL (IQR), n = 4,1291,135 (720-1,706)1,275 (803-1,833)0.0001Median absolute neutrophil count, cells/µL (IQR), n = 4,0716,177 (3,658-10,244)7,858 (4,943-11,867)0.0001Median NLR (IQR), n = 4,0615.5 (2,7-11.4)5.7 (3,2-11.7)0.04Platelet count, $\times 10^3$ /µL, mean (SD), n = 4,454222 (107)240 (105)0.0001Median Serum ferritin, µg/L (IQR) n = 3,168454 (189-977)580 (238-1,052)0.02Details of COVID-19 illness1,251/3,809 (40.7)331/1,616 (20.5)0.0001Management during COVID-191,126/3,765 (29.9)153/1,611 (9.5)0.0001Median cumulative dose of glucocorticoids in milligram52.8 (30-84)62.6 (30.2-120)0.0001Median no. days on glucocorticoid treatment (IQR), n = 2,8098 (5-12)10 (6.3-14)0.0001Zinc supplementation, n = 5,1791,502/3,631 (49.2)317/1,536 (20.6)0.0001Zinc supplementation, n = 5,16772/3,631 (49.2)317/1,536 (20.6)0.0001Zinc supplementation, n = 5,16772/3,631 (2.0)37/1,536 (2.4)0.41	Hemoglobin, g/dL, mean (SD), n = 4,506	12.2 (2.4)	12.1 (2.2)	0.11
Median absolute lymphocyte count, cells/µL (IQR), n = 4,1291,135 (720-1,706)1,275 (803-1,833)0.0001Median absolute neutrophil count, cells/µL (IQR), n = 4,0716,177 (3,658-10,244)7,858 (4,943-11,867)0.0001Median NLR (IQR), n = 4,0615.5 (2,7-11.4)5.7 (3,2-11.7)0.04Platelet count, $\times 10^3/\mu$ L, mean (SD), n = 4,454222 (107)240 (105)0.0001Median C-reactive protein mg/dL (IQR), n = 3,97226.7 (8,4-79.3)48.8 (20-102.5)0.0001Median serum ferritin, µg/L (IQR) n = 3,168454 (189-977)580 (238-1,052)0.02Details of COVID-19 illness1,551/3,809 (40.7)331/1,616 (20.5)0.0001ICU admission, n = 5,4251,551/3,809 (40.7)331/1,611 (9.5)0.0001Machanical ventilation, n = 5,3761,126/3,765 (29.9)153/1,611 (9.5)0.0001Management during COVID-19Glucocorticoid therapy, n = 5,4312,690/3,827 (70.3)1,200/1,604 (74.8)0.001Glucocorticoid use in the absence of hypoxemia, n = 5,021789/3,532 (22.3)509/1,489 (34.2)0.0001Median nullative dose of glucocorticoids in milligram52.8 (30-84)62.6 (30.2-120)0.0001Median no. days on glucocorticoid treatment (IQR), n = 2,8878 (5-12)10 (6.3-14)0.0001Zinc supplementation, n = 5,1791,502/3,633 (41.3)741/1,546 (47.9)0.0001Remdesivir, n = 5,16772/3,631 (2.0)317/1,536 (2.4)0.41	Total leukocyte count, cells/µL, mean (SD), n = 4,501	9,853 (6,844)	11,396 (6,110)	0.0001
Median absolute neutrophil count, cells/µL (IQR), n = 4,0716,177 (3,658–10,244)7,858 (4,943–11,867)0.0001Median NLR (IQR), n = 4,061 $5.5 (2.7-11.4)$ $5.7 (3.2-11.7)$ 0.04Platelet count, $\times 10^3$ /µL, mean (SD), n = 4,454222 (107)240 (105)0.0001Median C-reactive protein mg/dL (IQR), n = 3,97226.7 (8.4–79.3)48.8 (20–102.5)0.0001Median serum ferritin, µg/L (IQR) n = 3,168454 (189–977)580 (238–1,052)0.02Details of COVID-19 illness1,551/3,809 (40.7)331/1,616 (20.5)0.0001ICU admission, n = 5,4762,100/3,851 (54.5)751/1,625(46.2)0.0001ICU admission, n = 5,4751,551/3,809 (40.7)331/1,616 (20.5)0.0001Management during COVID-191,126/3,765 (29.9)153/1,611 (9.5)0.0001Glucocorticoid therapy, n = 5,4312,690/3,827 (70.3)1,200/1,604 (74.8)0.001Glucocorticoid use in the absence of hypoxemia, n = 5,021789/3,532 (22.3)509/1,489 (34.2)0.0001Median no. days on glucocorticoids in milligram52.8 (30–84)62.6 (30.2–120)0.0001equivalent of dexamethasone (IQR), n = 2,8091,502/3,633 (41.3)741/1,546 (47.9)0.0001Zinc supplementation, n = 5,1791,502/3,631 (49.2)317/1,536 (20.6)0.0001Tocilizumab, n = 5,16772/3,631 (2.0)37/1,536 (2.4)0.41	Median absolute lymphocyte count, cells/µL (IQR), n = 4,129	1,135 (720–1,706)	1,275 (803–1,833)	0.0001
Median NLR (IQR), n = 4,0615.5 (2.7-11.4)5.7 (3.2-11.7)0.04Platelet count, $\times 10^3$ /µL, mean (SD), n = 4,454222 (107)240 (105)0.0001Median C-reactive protein mg/dL (IQR), n = 3,97226.7 (8.4-79.3)48.8 (20-102.5)0.0001Median serum ferritin, µg/L (IQR) n = 3,168454 (189-977)580 (238-1,052)0.02Details of COVID-19 illness1,551/3,809 (40.7)331/1,616 (20.5)0.0001ICU admission, n = 5,4762,100/3,851 (54.5)751/1,625(46.2)0.0001ICU admission, n = 5,4761,26/3,765 (29.9)153/1,611 (9.5)0.0001Management during COVID-191,126/3,765 (29.9)153/1,611 (9.5)0.001Glucocorticoid therapy, n = 5,4312,690/3,827 (70.3)1,200/1,604 (74.8)0.001Glucocorticoid use in the absence of hypoxemia, n = 5,021789/3,532 (22.3)509/1,489 (34.2)0.0001Median cumulative dose of glucocorticoids in milligram52.8 (30-84)62.6 (30.2-120)0.0001equivalent of dexamethasone (IQR), n = 2,8091,502/3,633 (41.3)741/1,546 (47.9)0.0001Zinc supplementation, n = 5,1791,502/3,631 (49.2)317/1,536 (20.6)0.0001Tocilizumab, n = 5,16772/3,631 (2.0)37/1,536 (2.4)0.41	Median absolute neutrophil count, cells/µL (IQR), n = 4,071	6,177 (3,658–10,244)	7,858 (4,943–11,867)	0.0001
Platelet count, $\times 10^3/\mu$ L, mean (SD), n = 4,454222 (107)240 (105)0.0001Median C-reactive protein mg/dL (IQR), n = 3,97226.7 (8.4–79.3)48.8 (20–102.5)0.0001Median serum ferritin, $\mu g/L$ (IQR) n = 3,168454 (189–977)580 (238–1,052)0.02Details of COVID-19 illness1,551/3,809 (40.7)331/1,616 (20.5)0.0001Median c-reactive protein mg/dL (IQR) n = 5,4762,100/3,851 (54.5)751/1,625(46.2)0.0001ICU admission, n = 5,4751,551/3,809 (40.7)331/1,616 (20.5)0.0001Mechanical ventilation, n = 5,3761,126/3,765 (29.9)153/1,611 (9.5)0.0001Management during COVID-190.0010.001Glucocorticoid therapy, n = 5,4312,690/3,827 (70.3)1,200/1,604 (74.8)0.001Glucocorticoid use in the absence of hypoxemia, n = 5,021789/3,532 (22.3)509/1,489 (34.2)0.0001Median cumulative dose of glucocorticoids in milligram52.8 (30–84)62.6 (30.2–120)0.0001equivalent of dexamethasone (IQR), n = 2,80910 (6.3–14)0.00010.0001Zinc supplementation, n = 5,1791,502/3,633 (41.3)741/1,546 (47.9)0.0001Zinc supplementation, n = 5,16772/3,631 (2.0)37/1,536 (2.4)0.41	Median NLR (IQR), $n = 4,061$	5.5 (2.7–11.4)	5.7 (3.2–11.7)	0.04
Median C-reactive protein mg/dL (IQR), n = 3,972 26.7 (8.4–79.3) 48.8 (20–102.5) 0.0001 Median serum ferritin, $\mu g/L$ (IQR) n = 3,168 454 (189–977) 580 (238–1,052) 0.02 Details of COVID-19 illness 2,100/3,851 (54.5) 751/1,625(46.2) 0.0001 Hypoxemia, n = 5,476 2,100/3,851 (54.5) 751/1,625(46.2) 0.0001 ICU admission, n = 5,475 1,551/3,809 (40.7) 331/1,616 (20.5) 0.0001 Mechanical ventilation, n = 5,376 1,126/3,765 (29.9) 153/1,611 (9.5) 0.0001 Management during COVID-19 0.0001 0.0001 Glucocorticoid therapy, n = 5,431 2,690/3,827 (70.3) 1,200/1,604 (74.8) 0.001 Glucocorticoid use in the absence of hypoxemia, n = 5,021 789/3,532 (22.3) 509/1,489 (34.2) 0.0001 Median cumulative dose of glucocorticoids in milligram 52.8 (30–84) 62.6 (30.2–120) 0.0001 equivalent of dexamethasone (IQR), n = 2,809 10 (6.3–14) 0.0001 Zinc supplementation, n = 5,179 1,502/3,633 (41.3) 741/1,546 (47.9) 0.0001 Zinc supplementation, n = 5,167 72/3,631 (2.0) 37/1,536 (2.4) 0.41	Platelet count, \times 10 [°] /µL, mean (SD), n = 4,454	222 (107)	240 (105)	0.0001
Median serum ferritin, $\mu g/L$ (IQR) n = 3,168454 (189–977)580 (238–1,052)0.02Details of COVID-19 illness Hypoxemia, n = 5,4762,100/3,851 (54.5)751/1,625(46.2)0.0001ICU admission, n = 5,4251,551/3,809 (40.7)331/1,616 (20.5)0.0001Mechanical ventilation, n = 5,3761,126/3,765 (29.9)153/1,611 (9.5)0.0001Management during COVID-190.0010.001Glucocorticoid therapy, n = 5,4312,690/3,827 (70.3)1,200/1,604 (74.8)0.001Glucocorticoid use in the absence of hypoxemia, n = 5,021789/3,532 (22.3)509/1,489 (34.2)0.0001Median cumulative dose of glucocorticoids in milligram equivalent of dexamethasone (IQR), n = 2,80952.8 (30–84)62.6 (30.2–120)0.0001Zinc supplementation, n = 5,1791,502/3,633 (41.3)741/1,546 (47.9)0.0001Remdesivir, n = 5,1671,785/3,631 (49.2)317/1,536 (20.6)0.0001Tocilizumab, n = 5,16772/3,631 (2.0)37/1,536 (2.4)0.41	Median C-reactive protein mg/dL (IQR), n = 3,972	26.7 (8.4–79.3)	48.8 (20–102.5)	0.0001
Details of COVID-19 illnessHypoxemia, n = 5,4762,100/3,851 (54.5)751/1,625(46.2)0.0001ICU admission, n = 5,4251,551/3,809 (40.7)331/1,616 (20.5)0.0001Mechanical ventilation, n = 5,3761,126/3,765 (29.9)153/1,611 (9.5)0.0001Management during COVID-190.0010.001Glucocorticoid therapy, n = 5,4312,690/3,827 (70.3)1,200/1,604 (74.8)0.001Glucocorticoid use in the absence of hypoxemia, n = 5,021789/3,532 (22.3)509/1,489 (34.2)0.0001Median cumulative dose of glucocorticoids in milligram equivalent of dexamethasone (IQR), n = 2,80952.8 (30–84)62.6 (30.2–120)0.0001Zinc supplementation, n = 5,1791,502/3,633 (41.3)741/1,546 (47.9)0.0001Zinc supplementation, n = 5,1671,785/3,631 (49.2)317/1,536 (20.6)0.0001Tocilizumab, n = 5,16772/3,631 (2.0)37/1,536 (2.4)0.41	Median serum ferritin, $\mu g/L$ (IQR) n = 3,168	454 (189–977)	580 (238–1,052)	0.02
Hypoxemia, n = 5,476 $2,100/3,851(54.5)$ $75171,625(46.2)$ 0.0001 ICU admission, n = 5,425 $1,551/3,809(40.7)$ $331/1,616(20.5)$ 0.0001 Mechanical ventilation, n = 5,376 $1,126/3,765(29.9)$ $153/1,611(9.5)$ 0.0001 Management during COVID-19 $2,690/3,827(70.3)$ $1,200/1,604(74.8)$ 0.001 Glucocorticoid therapy, n = 5,431 $2,690/3,827(70.3)$ $1,200/1,604(74.8)$ 0.001 Median cumulative dose of glucocorticoids in milligram $52.8(30-84)$ $62.6(30.2-120)$ 0.0001 equivalent of dexamethasone (IQR), n = 2,809 $8(5-12)$ $10(6.3-14)$ 0.0001 Zinc supplementation, n = 5,179 $1,502/3,633(41.3)$ $741/1,546(47.9)$ 0.0001 Remdesivir, n = 5,167 $1,785/3,631(49.2)$ $317/1,536(20.6)$ 0.0001 Tocilizumab, n = 5,167 $72/3,631(2.0)$ $37/1,536(2.4)$ 0.41	Details of COVID-19 illness		754/4 005/40 0	0.0004
ICU admission, n = 5,4251,551/3,809 (40.7) $331/1,616 (20.5)$ 0.0001 Mechanical ventilation, n = 5,3761,126/3,765 (29.9)153/1,611 (9.5) 0.0001 Management during COVID-19Glucocorticoid therapy, n = 5,4312,690/3,827 (70.3)1,200/1,604 (74.8) 0.001 Glucocorticoid use in the absence of hypoxemia, n = 5,021789/3,532 (22.3)509/1,489 (34.2) 0.0001 Median cumulative dose of glucocorticoids in milligram52.8 (30–84)62.6 (30.2–120) 0.0001 equivalent of dexamethasone (IQR), n = 2,80910 (6.3–14) 0.0001 Zinc supplementation, n = 5,1791,502/3,633 (41.3)741/1,546 (47.9) 0.0001 Remdesivir, n = 5,1671,785/3,631 (49.2)317/1,536 (20.6) 0.0001 Tocilizumab, n = 5,16772/3,631 (2.0)37/1,536 (2.4) 0.41	Hypoxemia, $n = 5,476$	2,100/3,851 (54.5)	751/1,625(46.2)	0.0001
Mechanical ventilation, n = 5,376 1,126/3,765 (29.9) 153/1,611 (9.5) 0.0001 Management during COVID-19 $3,76$ 2,690/3,827 (70.3) 1,200/1,604 (74.8) 0.001 Glucocorticoid therapy, n = 5,431 $2,690/3,827 (70.3)$ $1,200/1,604 (74.8)$ 0.001 Median cumulative dose of glucocorticoids in milligram $52.8 (30-84)$ $62.6 (30.2-120)$ 0.0001 equivalent of dexamethasone (IQR), n = 2,809 Median no. days on glucocorticoid treatment (IQR), n = 2,887 $8 (5-12)$ $10 (6.3-14)$ 0.0001 Zinc supplementation, n = 5,179 $1,502/3,633 (41.3)$ $741/1,546 (47.9)$ 0.0001 Remdesivir, n = 5,167 $1,785/3,631 (49.2)$ $317/1,536 (20.6)$ 0.0001 Tocilizumab, n = 5,167 $72/3,631 (2.0)$ $37/1,536 (2.4)$ 0.41	ICU admission, n = 5,425	1,551/3,809 (40.7)	331/1,616 (20.5)	0.0001
Management during COVID-19 2,690/3,827 (70.3) 1,200/1,604 (74.8) 0.001 Glucocorticoid therapy, n = 5,431 2,690/3,827 (70.3) 1,200/1,604 (74.8) 0.001 Glucocorticoid use in the absence of hypoxemia, n = 5,021 789/3,532 (22.3) 509/1,489 (34.2) 0.0001 Median cumulative dose of glucocorticoids in milligram 52.8 (30–84) 62.6 (30.2–120) 0.0001 equivalent of dexamethasone (IQR), n = 2,809 10 (6.3–14) 0.0001 Zinc supplementation, n = 5,179 1,502/3,633 (41.3) 741/1,546 (47.9) 0.0001 Remdesivir, n = 5,167 1,785/3,631 (49.2) 317/1,536 (20.6) 0.0001 Tocilizumab, n = 5,167 72/3,631 (2.0) 37/1,536 (2.4) 0.41	Mechanical Ventilation, n = 5,376	1,126/3,765 (29.9)	153/1,611 (9.5)	0.0001
Giucocorticoid inerapy, n = 5,431 $2,590/3,527$ (70.3) $1,200/1,504$ (74.8) 0.001 Glucocorticoid use in the absence of hypoxemia, n = 5,021 $789/3,532$ (22.3) $509/1,489$ (34.2) 0.0001 Median cumulative dose of glucocorticoids in milligram 52.8 (30–84) 62.6 (30.2–120) 0.0001 equivalent of dexamethasone (IQR), n = 2,809Median no. days on glucocorticoid treatment (IQR), n = 2,887 8 (5–12) 10 (6.3–14) 0.0001 Zinc supplementation, n = 5,179 $1,502/3,633$ (41.3) $741/1,546$ (47.9) 0.0001 Remdesivir, n = 5,167 $1,785/3,631$ (49.2) $317/1,536$ (20.6) 0.0001 Tocilizumab, n = 5,167 $72/3,631$ (2.0) $37/1,536$ (2.4) 0.41	Management during COVID-19	2 000/2 007 (70 2)	4 200/4 004 (74 0)	0.004
Giudocontrolid use in the absence of hypoxemia, $n = 5,021$ $789/3,532(22.3)$ $509/1,489(34.2)$ 0.0001 Median cumulative dose of glucocorticoids in milligram $52.8(30-84)$ $62.6(30.2-120)$ 0.0001 equivalent of dexamethasone (IQR), $n = 2,809$ $52.8(30-84)$ $62.6(30.2-120)$ 0.0001 Zinc supplementation, $n = 5,179$ $1,502/3,633(41.3)$ $741/1,546(47.9)$ 0.0001 Remdesivir, $n = 5,167$ $1,785/3,631(49.2)$ $317/1,536(20.6)$ 0.0001 Tocilizumab, $n = 5,167$ $72/3,631(2.0)$ $37/1,536(2.4)$ 0.41	Glucocorticold therapy, $n = 5,431$	2,090/3,827 (70.3)	1,200/1,604 (74.8)	0.001
Median cumulative dose of glucocorticolds in minigram $52.8 (30-84)$ $62.6 (30.2-120)$ 0.0001 equivalent of dexamethasone (IQR), n = 2,809Median no. days on glucocorticold treatment (IQR), n = 2,887 $8 (5-12)$ $10 (6.3-14)$ 0.0001 Zinc supplementation, n = 5,179 $1,502/3,633 (41.3)$ $741/1,546 (47.9)$ 0.0001 Remdesivir, n = 5,167 $1,785/3,631 (49.2)$ $317/1,536 (20.6)$ 0.0001	Giucocorticold use in the absence of hypoxemia, h = 5,021 Median sumulative data of alugeastication in milligram	789/3,532 (22.3)	509/1,489 (34.2)	0.0001
Median no. days on glucocorticoid treatment (IQR), n = 2,887 8 (5–12) 10 (6.3–14) 0.0001 Zinc supplementation, n = 5,179 1,502/3,633 (41.3) 741/1,546 (47.9) 0.0001 Remdesivir, n = 5,167 1,785/3,631 (49.2) 317/1,536 (20.6) 0.0001 Tocilizumab, n = 5,167 72/3,631 (2.0) 37/1,536 (2.4) 0.41	Median cumulative dose of glucocorticolds in milligram	52.8 (30–84)	62.6 (30.2–120)	0.0001
Zinc supplementation, $n = 5,179$ 1,502/3,633 (41.3)741/1,546 (47.9)0.0001Remdesivir, $n = 5,167$ 1,785/3,631 (49.2)317/1,536 (20.6)0.0001Tocilizumab, $n = 5,167$ 72/3,631 (2.0)37/1,536 (2.4)0.41	Equivalent of dexametriasone (IQR), $\Pi = 2,009$ Median no. dove on glucoportionid treatment (IQR), $n = 2,997$	9 (5 12)	10 (6.2, 14)	0.0001
Zine supplementation, $n = 5, 179$ 1,502/3,603 (41.5)74/71,546 (47.9)0.0001Remdesivir, $n = 5, 167$ 1,785/3,631 (49.2)317/1,536 (20.6)0.0001Tocilizumab, $n = 5, 167$ 72/3,631 (2.0)37/1,536 (2.4)0.41	Nieuran no. uays on giucoconicolu treatment (IQR), $\Pi = 2,887$ Zine supplementation $n = 5,170$	0 (U-12) 1 502/2 622 (41 2)	10 (0.3-14) 7/1/1 5/6 (/7 0)	0.0001
Tocilizumab, n = $5,167$ $72/3,631 (2.0)$ $37/1,536 (2.4)$ 0.0001	$2 \ln 6$ supplementation, $\Pi = 0, \Pi 9$ Remdesivir, $n = 5.167$	1,302/3,033 (41.3) 1 785/3 631 (40.2)	141/1,040 (47.9) 317/1 536 (20.6)	0.0001
12/3,031 (2.0) 37/1,030 (2.4) 0.41	Tocilizumah $n = 5.167$	72/3 631 /2 0)	37/1 526 (20.0)	0.0001
Baricitinih n = 5 167 38/3 631 (1.0) 13/1 536 (0.8) 0.50	Baricitinib n = 5.167	38/3 631 (2.0)	13/1 536 (2.4)	0.41
Antibarterial Herany n = 5 396 2 467(3 841 (64 2) 057(1.0) 0.00 (0.0)	Antihacterial therapy $n = 5.396$	2 467/3 841 (64 2)	952/1 555 (61 2)	0.00
Antifungal therapy before CAM, n = 5.039 174/3.513 (5.0) 68/1.526 (4.5) 0.45	Antifungal therapy before CAM. n = 5.039	174/3.513 (5.0)	68/1.526 (4.5)	0.45

*Values are no. observed/total no. (%) unless otherwise indicated. CAM, COVID-19–associated mucormycosis; DKA, diabetic ketoacidosis; DM, diabetes mellitus; ICU, intensive care unit; IQR, interquartile range; NLR, neutrophil-to-lymphocyte ratio.

†A single person might have had >1 risk factor; hence the numbers do not sum to 5,644.

 ξ others include neutropenia (n = 3) and primary immunodeficiency (n = 1). §Others include neurologic, endocrinologic, and rheumatologic illnesses.



Figure. Percentages of hypoxemic and nonhypoxemic participants receiving cumulative glucocorticoid doses above and below the current recommendations (cumulative dexamethasone dose equivalent to 60 mg) as determined in multicenter case-control study of COVID-19–associated mucormycosis outbreak, India, January–June 2021. Case-patients are shown in black and control-patients are shown in gray. More case-patients than control-patients had received higher-than-recommended doses of glucocorticoids.

Confounders

Chronic comorbidities (chronic liver, kidney, lung, and other diseases) were present in 37% of study participants and were seen more often in controls than in CAM patients. Significantly higher plasma glucose, neutrophil-to-lymphocyte ratio, platelet count, C-reactive protein, and serum ferritin were seen in CAM patients during their hospitalizations for COVID-19. We identified >1 host factors for mucormycosis in 46.9% of controls versus 81.8% of case-patients (p = 0.0001). The proportion of diabetes mellitus was significantly higher in case-patients (80.9% vs. 45.1%; p = 0.0001) than in controls. Recent-onset diabetes mellitus was similar in both the study groups, whereas diabetic ketoacidosis was significantly more common among CAM than in the controls (5.2% vs. 2.7%; p = 0.0003). We found hypoxemia during acute COVID-19 (54.5% vs. 46.2%), admission to an intensive care unit

(40.7% vs. 20.5%), and mechanical ventilation (29.9% vs. 9.5%) significantly higher among control-patients.

Association of COVID-19 Treatment Practices with CAM

We found the cumulative dose of glucocorticoid used (OR 1.006, 95% CI 1.004–1.007) and zinc supplementation (OR 2.76, 95% CI 2.24–3.40) independently associated with CAM, in addition to elevated C-reactive protein, host factors (renal transplantation, diabetes mellitus, diabetic ketoacidosis during COVID-19), and rural residence (Table 2). Hypoxemia during COVID-19 and comorbidities were associated with lower odds of CAM. The results were similar on a complete case analysis (Appendix Table 3). Because the proportion of persons with hypoxemia and comorbidities was higher in COVID-19 controls than in CAM patients, we also performed a subgroup analysis (hypoxemic vs. nonhypoxemic controls and any

Table 2. Multivariate logistic regression analysis showing factors associated with CAM, India, January–June 2021*			
Parameter	Adjusted OR (95% CI)	p value	
Female sex	0.92 (0.74–1.14)	0.46	
Rural residence	2.88 (2.12–3.79)	0.0001	
Risk factor			
No risk factor	Referent		
Diabetes mellitus	6.72 (5.45–8.28)	0.0001	
Renal transplantation	7.58 (3.31–17.40)	0.0001	
Others†	1.20 (0.67–2.18)	0.54	
Presence of any comorbidity	0.50 (0.39–0.63)	0.0001	
Hypoxia during COVID-19	0.26 (0.21–0.32)	0.0001	
Diabetic ketoacidosis during COVID-19	4.41 (2.03–9.60)	0.0001	
Cumulative glucocorticoid dose for COVID-19‡	1.006 (1.004–1.007)	0.0001	
Zinc supplementation during COVID-19	2.76 (2.24–3.40)	0.0001	
C-reactive protein at admission	1.004 (1.002–1.006)	0.0001	
Serum ferritin, µg/L	1.00 (1.00–1.00)	0.21	
Neutrophil-to-lymphocyte ratio	1.0 (0.99–1.01)	0.92	
*CAM COVID 10, accessized museumusesis	· · ·		

*CAM, COVID-19–associated mucormycosis

†Includes malignancies, hematological malignancies, immunosuppressive therapy, HIV, and others.

‡In milligram equivalent of dexamethasone.

comorbidity vs. no comorbidity; Appendix Tables 4, 5). We found the primary exposure of interest (COV-ID-19 treatment factors) significantly associated with CAM in both the subgroups (Appendix Tables 4, 5).

We also assessed the association of inappropriate glucocorticoid therapy (i.e., glucocorticoids administered in the absence of hypoxemia) with CAM. In an alternative logistic regression model, we replaced glucocorticoid doses with inappropriate glucocorticoid therapy (Appendix Table 6) and found inappropriate therapy also significantly associated with CAM.

Additional Analyses of Clinical Features, Diagnosis, Treatment, and Outcome of CAM

CAM occurred nonconcurrently (>7 days after COV-ID-19 diagnosis) in 1,405 (81.7%) of 1,720 persons; the remaining 315 (18.3%) cases were concurrent with the COVID-19 illness (within 7 days of diagnosis). The duration between COVID-19 and the diagnosis of CAM was shorter for those hospitalized for COVID-19 (mean 20, 95% CI 19-21 days) versus those isolated at home (mean 25, 95% CI 24-27 days). The median duration between symptoms of CAM and confirmation of the diagnosis was 6 (interquartile range 3-10) days (n = 1,024 persons). Rhino-orbital mucormycosis accounted for 92.4% of the cases, followed by pulmonary (7%) and other sites (0.6%). The proportion of pulmonary mucormycosis was higher in persons who had undergone organ transplants (17.2%) and persons with hematological malignancies (33.3%) than in those with diabetes mellitus (6.4%). Of the 1,602 patients with rhino-orbital mucormycosis, we noted intracranial extension in 261 (16.3%) cases. Nearly two thirds (1,143/1,733; 66.0%) of the CAM patients had evidence of mucormycosis from >1 sample (smear, culture, or histopathology) (Table 3). The most common etiologic agent causing mucormycosis was Rhizopus spp. (mainly R. arrhizus). The other reported organisms included Mucor and Rhizomucor spp.,

Table 3. Diagnosis, treatment practices, and survival in patients with CAM, India, January-June	2021*
Parameter	No. observed/total no. (%)
Site of mucormycosis†	
Rhino-orbito-cerebral	
Sinus	1,526/1,733 (88.1)
Orbit	789/1,733 (45.5)
Palate	373/1,733 (21.5)
Jaw	315/1,733 (18.2)
Brain	261/1,733 (15.1)
Blackening of skin over face	102/1,733 (5.9)
Cavernous sinus	44/1,733 (2.5)
Skull base	65/1,733 (3.8)
Pulmonary†	122/1,733 (7.0)
Cutaneous or soft tissue	5/1,733 (0.3)
Gastrointestinal	2/1,733 (0.1)
Renal†	2/1,733 (0.1)
Diagnosis of mucormycosis	
Microscopy alone	352/1,733 (20.3)
Culture growth of Mucorales alone	61/1,733 (3.5)
Histopathology alone	177/1,733 (10.2)
>1 evidence (smear, culture, or histopathology) of mucormycosis	1,143/1,733 (66.0)
Treatment practices	
Intended therapy could not be administered	321/1,526 (21.0)
Missed doses due to drug non-availability	248/1,457 (17.0)
Primary therapy	
Any formulation of amphotericin B‡	1,634/1,733 (94.3)
Primary combination therapy§	
Any combination	699/1,733 (41.6)
Amphotericin B and posaconazole	541/699 (77.4)
Amphotericin B and isavuconazole	121/699 (17.3)
Amphotericin B and isavuconazole or posaconazole	37/699 (5.3)
Surgery	
Combined medical and surgical treatment	1,449/1,773 (83.6)
Survival	
Death by 6 weeks	442/1,546 (28.6)
Death by 12 weeks	473/1,471 (32.2)

*CAM, COVID-19-associated mucormycosis

†Total number does not sum to 1,733 since patients might have had involvement at >1 site. There were 18 cases of disseminated mucormycosis (17 had pulmonary in addition to rhino-orbital, while 1 person had rhino-orbito-cerebral and renal mucormycosis).

‡Of the 1,634 persons receiving amphotericin B, liposomal amphotericin B alone was used in 1,210 (74.1%) patients, amphotericin B deoxycholate in 143 (8.7%) patients, amphotericin B lipid emulsion in 21 (1.3%) patients, >1 formulation in 236 (14.4%) patients, and the information was not clear in 24 (1.5%) patients.

\$Primary therapy with a combination of amphotericin and isavuconazole or posaconazole within the first 14 days was used in 699/1,733 (41.6%) patients.

Table 4. Factors associated with death at 12 weeks in persons with CAW, india, 5	anuary–June 2021	
Parameter	Adjusted odds ratio (95% CI)	p value
Age	1.02 (1.01–1.04)	0.0001
Sex	1.00 (0.74–1.34)	0.99
Risk factor		
No risk factor	Referent	
Diabetes mellitus	1.27 (0.93–1.74)	0.13
Renal transplantation	2.66 (1.04–6.81)	0.04
Others†	1.51 (0.55–4.18)	0.42
Presence of any comorbidity	1.38 (0.97–1.97)	0.08
Hypoxemia during COVID-19 illness	1.31 (0.93–1.83)	0.12
Site of mucormycosis		
Rhino-orbital mucormycosis	Referent	
Rhino-orbital mucormycosis with brain involvement	2.30 (1.66–3.19)	0.0001
Other sites‡	1.44 (0.90–2.32)	0.13
Primary combination medical therapy	0.53 (0.37–0.77)	0.001
Combined medical and surgical treatment	0.20 (0.14–0.27)	0.0001
*CAM, COVID-19–associated mucormycosis.	· · · · ·	
tincludes bematological malignancies, immunosuppressive therapy, and HIV infection		

‡Includes pulmonary, gastrointestinal, disseminated, and renal mucormycosis.

and rarely Cunninghamella, Syncephalastrum, Apophyso*myces, Lichtheimia* spp., and others.

The treatment of CAM varied widely and was influenced by antifungal drug availability. The intended antifungal agent could not be administered in 21.0% (321/1,526) of cases, and ≥ 1 dose was missed because the antifungal drugs were unavailable in 17% (248/1,547) of CAM cases. Amphotericin B was the most prescribed antifungal agent. A combination of antifungal agents was used for primary therapy in 41.6% of patients. Surgery was performed in most case-patients (1,449/1,733; 83.6%). The mortality rate at 6 weeks (data available for 89.2% of cases) was 28.6% and at 12 weeks (data available for 84.9% cases) was 32.2%.

We found surgical resection and primary antifungal combination therapy independently associated with better odds of survival at 12 weeks (Table 4). We also found increasing age and intracranial extension associated with worse odds of survival after adjusting for sex, comorbidities, and COVID-19-related hypoxemia. The results were similar on a complete case analysis (Appendix Table 7).

Discussion

In this large case-control study, we found that glucocorticoid use and zinc supplementation in the treatment of COVID-19 were significantly associated with CAM. In addition, several host factors for mucormycosis (i.e., renal transplantation, diabetes mellitus, and diabetic ketoacidosis), elevated C-reactive protein, and rural residence were also associated with CAM. The unprecedented rise in the number of CAM cases during the second wave of the COVID-19 pandemic indicates that COVID-19 or its treatment had a role in causing CAM (2,16).

We provide strong evidence to incriminate glucocorticoid therapy in CAM even after adjusting for

host factors. Our results strengthen the current recommendation of avoiding glucocorticoid use in CO-VID-19 patients not experiencing hypoxemia (17,18). More critically, we found that the cumulative glucocorticoid dose is also a contributory factor for CAM. Thus, even in hypoxemic COVID-19 patients, glucocorticoids should be used judiciously (dexamethasone at a dose of 6 mg $1 \times /d$ for up to 10 days or until hospital discharge, whichever is earlier) (19). We also found zinc supplementation an independent factor associated with CAM. A small study suggested a protective role of zinc in CAM (6), but 2 other studies found an association between zinc and CAM (20,21). The biologic plausibility (22) and in vitro evidence of abundant growth of Mucorales strains (isolated from CAM patients) demonstrated on zinc-supplemented media supports the possible role of zinc in causing CAM (20). Although we found a few factors related to the severity and treatment of COVID-19 in the development of CAM, we did not evaluate the role of CO-VID-19-related immune dysfunction in this study. Nonetheless, we provide weak indirect evidence implicating the severity of COVID-19 illness (elevated C-reactive protein) in the development of CAM. Finally, rural residence was significantly associated with CAM and might be attributed to higher levels of fungal spores in the rural environment (23–26).

The time to develop CAM was significantly shorter in hospitalized persons than in persons isolated at home. This finding could suggest hospital-acquired mucormycosis; however, the hospitalization could simply mean that severe COVID-19 led to mucormycosis early in the course of illness or, more likely, that CAM was diagnosed earlier simply because these persons were hospitalized. Based on a few media reports, 1 review hypothesized that the burning of cow dung led to the mucormycosis outbreak in India (27).

However, a recent experimental aeromycological study found no evidence for this theory (25).

Several case-control studies (n = 13) have assessed the risk factors associated with CAM (Appendix Table 8) (6,7,20,21,28-36). In 8 studies (sample sizes ranging from 46 to 870), risk factors for CAM were assessed using multivariate analysis (6,7,29-33,35). Diabetes mellitus and glucocorticoid therapy were shown to be the major contributors for CAM in the case-control studies and large case series (2,3,6,21,35,37). Further, in addition to zinc and elevated inflammatory markers (C-reactive protein), which were also associated with CAM in this study, the use of cloth masks, nasal washing during COVID-19, and elevated serum glucose-regulated protein 78 were other possible associations described in smaller case-control studies (29,30,33). In our study, mean glycated hemoglobin values were significantly higher in the CAM cases. In another study, optimal glycemic control and adherence to low-dose glucocorticoid protocol eliminated the occurrence of mucormycosis in a COVID-19 intensive care unit even during the surge in CAM cases (38). Unfortunately, because of the overwhelming case burden, many COVID-19 patients were taking various prescription or over-the-counter medications (including glucocorticoids and zinc) unmonitored, which probably contributed to the outbreak.

We found lower rates of mortality in mucormycosis patients than in previous reports (11,39,40). The lower mortality rate in our study might be attributed to several factors. First, more severe forms of the disease, including pulmonary and disseminated mucormycosis, could have been underrepresented (41,42). For instance, pulmonary mucormycosis accounted for only 7% of the cases in this study (vs. 13% in a pre-COVID-19 large multicenter study from India) (11). Second, the increased awareness about mucormycosis because of the outbreak led to timely diagnosis (median time to diagnosis 6 days) and surgical intervention in a higher percentage of cases (84%) than in the pre-COVID-19 era (62%) (11). Also, the predisposing factors in CAM cases, such as glucocorticoid therapy and hyperglycemia, were mostly reversible. The use of primary combination antifungal therapy might have contributed to improved outcomes. A previous multicenter observational study on CAM also indicated that combining amphotericin B with posaconazole might be associated with better outcomes than monotherapy (2). However, attributing the benefit of combination treatment to survival without a randomized clinical trial is difficult. Our results also confirm the existing knowledge that surgical treatment is associated with better outcomes in mucormycosis (1,11).

The first limitation of our study is that data were collected during the peak of the pandemic with limited resources, and some information was missing as a result. Although our study supports the definite association of glucocorticoids with CAM, the same might not be accurate for zinc. Zinc might be synergistic to glucocorticoids or other factors in the development of CAM. However, it was an independent risk factor across different subgroups and in different multivariate models. Although we could obtain information on zinc supplementation during the treatment of COVID-19, the wide variation in prescription practice, over-the-counter availability of drugs, and use of different formulations and dosages precluded establishing a dose-response relationship between zinc and CAM. Thus, prospective studies and animal experiments are warranted to establish the association of zinc with CAM. Even though we enrolled a large number of control-patients, the control-patients were sicker than case-patients. This difference in severity of COVID-19 symptoms influenced a few of our results. For instance, the presence of any comorbidity and the need for mechanical ventilation were associated with a lower risk for CAM. One could argue that our association of the primary exposure variable with CAM is invalid because the control-patients critically ill with COVID-19 might not have survived long enough for CAM to develop. Imperfect matching for COVID-19 severity is thus a major limitation. To adjust for the severity of COVID-19, we performed a subgroup analysis in which we compared the CAM patients with either hypoxemic or nonhypoxemic COVID-19 control-patients. We found the COVID-19 treatment factors (primary exposure) remained significantly associated with CAM in both groups (Appendix Table 4). We restricted our data collection to information that could be accessed reliably despite the pandemic. Thus, we cannot exclude residual confounders. Not all the participating centers could provide the desired number of control subjects, and there was variation in mortality reported from different centers (Appendix Table 1). A referral bias to the participating study centers and underrecognition of certain forms of mucormycosis (pulmonary and others) could have influenced our observations. We could not assess the burden of CAM among COVID-19 case-patients. Also, we included cases diagnosed by conventional microbiological techniques, and we might have missed several presumed cases of mucormycosis. However, the objective of our study was to evaluate the risk factors in a case-control model, and hence we included confirmed cases only. Finally, the results might not be generalizable because the information is from just 1 country. The key strength of our study is the large sample size and representation from across the country, which lends credibility to our observations.

In conclusion, we found several treatment practices associated with CAM in addition to rural residence and host factors. Our results suggest the judicious use of COVID-19 therapies and optimal glycemic control to prevent CAM.

Other members of the MuCovi-2 network: Goverdhan Dutt Puri, Inderpaul Singh Sehgal, Ashish Bhalla, Ram Gopalakrishnan, Ritu Kumari, Prayag Mathukia, Ketan Patel, Mohnish Grover, Pradipta Parida, Aaron Charles Lobo, Ruchita Chhabra, Sahana Devakumar, Rajeshwari V, Mohammed Ismail, Ledo Thankachan, Adla Sandhya Rani, Garela Parimala Devi, Alok Thakar, Anjan Trikha, and Naveet Wig

Funding was provided by the World Health Organization.

A.K.P. received honoraria and lecture fees from Gilead Sciences, Pfizer (India), Intas Pharmaceuticals, Mylan (India), Bharat Serum Vaccine Ltd, and Cipla India Ltd. T.S. received lecture fees from Mylan (India), Cipla India Ltd, MSD, Intas Pharmaceuticals, Pfizer (India), Glenmark Pharmaceuticals.

A.C. and R.A. conceptualized the study. V.M., S.M.R., D.T., M.R.S., A.K.P., P.S.S., A.T., S.B., V.G., J.S., S.M., V.K.H., V.N.M., A.S., N.S., R.P.S.S., S.P., R.M., T.S., P.S., V.G., V.N., P.P., D.P., I.X., P.S., N.P., G.D.R., R.S.P., K.P., A.D., A.V., S.K.S., P.A.P., D.R., S.S., B.R., P.V., K.P.P., S.P., P.G., P.H., S.N.D., S.N., H.K., S.B., K.K.K., N.S., M.N., A.P., G.S., and P.D. curated data. V.M., R.A., and A.C. conducted the formal analysis. A.C. acquired funding. R.A., A.C., S.M.R., and V.M. implemented the study methodology. A.C., R.A., and S.M.R. oversaw the project administration and provided the required resources. A.C., R.A., S.M.R., A.K.P., and P.S. validated the data. V.M. and R.A. wrote the original draft. S.M.R., D.T., M.R.S., A.K.P., P.S.S., A.T., S.B., V.G., J.S., S.M., V.K.H., V.N.M., A.S., N.S., R.P.S.S., S.P., R.M., T.S., P.S., V.G., V.N., P.P., D.P., I.X., P.S., N.P., G.D.R., R.S.P., K.P., A.D., A.V., S.K.S., P.A.P., D.R., S.S., B.R., P.V., K.P.P., S.P., P.G., P.H., S.N.D., S.N., H.K., S.B., K.K.K., N.S., M.N., A.P., G.S., P.D., and A.C. reviewed and edited the article. The first and corresponding authors had full access to the data and vouch for the data integrity.

About the Author

Dr. Muthu is a pulmonologist at the Postgraduate Institute of Medical Education and Research, Chandigarh, India. His research interests include mucormycosis and allergic bronchopulmonary aspergillosis.

References

- Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al.; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405–21. https://doi.org/10.1016/ S1473-3099(19)30312-3
- Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al.; MucoCovi Network3. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 2021;27:2349–59. https://doi.org/10.3201/eid2709.210934
- Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al.; members of the Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) Study Group. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), report 1. Indian J Ophthalmol. 2021;69:1670–92. https://doi.org/10.4103/ ijo.IJO_1565_21
- Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al.; ECMM and ISHAM collaborators. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3:e543–52. https://doi.org/10.1016/ S2666-5247(21)00237-8
- Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus disease (COVID-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021;186:289–98. https://doi.org/10.1007/s11046-021-00528-2
- Arora U, Priyadarshi M, Katiyar V, Soneja M, Garg P, Gupta I, et al. Risk factors for coronavirus disease– associated mucormycosis. J Infect. 2022;84:383–90. https://doi.org/10.1016/j.jinf.2021.12.039
- Kumar H M, Sharma P, Rudramurthy SM, Sehgal IS, Prasad KT, Pannu AK, et al. Serum iron indices in COVID-19-associated mucormycosis: a case-control study. Mycoses. 2022;65:120–7. https://doi.org/10.1111/myc.13391
- Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021;186:739–54. https://doi.org/10.1007/ s11046-021-00584-8
- Biswal M, Gupta P, Kanaujia R, Kaur K, Kaur H, Vyas A, et al. Evaluation of hospital environment for presence of Mucorales during COVID-19-associated mucormycosis outbreak in India – a multi-centre study. J Hosp Infect. 2022;122:173–9. https://doi.org/10.1016/j.jhin.2022.01.016
- Prakash H, Singh S, Rudramurthy SM, Singh P, Mehta N, Shaw D, et al. An aero mycological analysis of Mucormycetes in indoor and outdoor environments of northern India. Med Mycol. 2020;58:118–23. https://doi.org/ 10.1093/mmy/myz031
- Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26:944.e9–e15.
- 12. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational

studies. BMJ. 2007;335:806-8. https://doi.org/10.1136/ bmj.39335.541782.AD

- 13. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al.; Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367–76. https://doi.org/10.1093/cid/ciz1008
- Muthu V, Agarwal R, Patel A, Kathirvel S, Abraham OC, Aggarwal AN, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis. 2022;22:e240-e253.
- Rudramurthy SM, Hoenigl M, Meis JF, Cornely OA, Muthu V, Gangneux JP, et al.; ECMM and ISHAM. ECMM/ISHAM recommendations for clinical management of COVID-19-associated mucormycosis in low- and middle-income countries. Mycoses. 2021;64:1028–37. https://doi.org/10.1111/myc.13335
- Seidel D, Simon M, Sprute R, Lubnow M, Evert K, Speer C, et al. Results from a national survey on COVID-19– associated mucormycosis in Germany: 13 patients from six tertiary hospitals. Mycoses. 2022;65:103–9. https://doi.org/10.1111/myc.13379
- Muthu V, Sehgal IS, Dhooria S, Prasad KT, Aggarwal AN, Agarwal R. Corticosteroids for non-severe COVID-19: primum non nocere. Indian J Crit Care Med. 2022;26:403-4. https://doi.org/10.5005/jp-journals-10071-24138
- Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for COVID-19. BMJ. 2020;370:m3379. https://doi.org/ 10.1136/bmj.m3379
- Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al.; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693–704. https://doi.org/10.1056/NEJMoa2021436
- Muthu V, Kumar M, Paul RA, Zohmangaihi D, Choudhary H, Rudramurthy SM, et al. Is there an association between zinc and COVID-19-associated mucormycosis? Results of an experimental and clinical study. Mycoses. 2021;64:1291–7. https://doi.org/10.1111/myc.13365
- Kumar S, Acharya S, Jain S, Shukla S, Talwar D, Shah D, et al. Role of zinc and clinicopathological factors for COVID-19-associated mucormycosis (CAM) in a rural hospital of central India: a case-control study. Cureus. 2022;14:e22528. https://doi.org/10.7759/cureus.22528
- Foster JW, Waksman SA. The specific effect of zinc and other heavy metals on the growth and nutrition of Rhizopus. J Bacteriol. 1939;37:599–617. https://doi.org/10.1128/ jb.37.6.599-617.1939
- Adhikari A, Sen MM, Gupta-Bhattacharya S, Chanda S. Airborne viable, non-viable, and allergenic fungi in a rural agricultural area of India: a 2-year study at five outdoor sampling stations. Sci Total Environ. 2004;326:123–41. https://doi.org/10.1016/j.scitotenv.2003.12.007
- Abrego N, Crosier B, Somervuo P, Ivanova N, Abrahamyan A, Abdi A, et al. Fungal communities decline with urbanization-more in air than in soil. ISME J. 2020;14:2806–15. https://doi.org/10.1038/s41396-020-0732-1
- 25. Kathirvel S, Muthu V, Rudramurthy SM, Kaur H, Chakrabarti A, Agarwal R. Could cattle dung burning have

contributed to the epidemic of COVID-19-associated mucormycosis in India? Results of an experimental aero-mycological study. Mycoses. 2022;65:1024–9. https://doi.org/10.1111/myc.13487

- Ghosh AK, Singh R, Reddy S, Singh S, Rudramurthy SM, Kaur H, et al. Evaluation of environmental Mucorales contamination in and around the residence of COVID-19– associated mucormycosis patients. Front Cell Infect Microbiol. 2022;12:953750. https://doi.org/10.3389/fcimb.2022.953750
- Skaria J, John TM, Varkey S, Kontoyiannis DP. Are unique regional factors the missing link in India's COVID-19– associated mucormycosis crisis? MBio. 2022;13:e0047322. https://doi.org/10.1128/mbio.00473-22
- Bansal SB, Rana A, Babras M, Yadav D, Jha P, Jain M, et al. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients. Transpl Infect Dis. 2022;24:e13777. https://doi.org/10.1111/tid.13777
- Karat S, Lobo AC, Satish D, Devaraj R, Manjooran RR, Nithyanandam S. Uncontrolled diabetes mellitus exacerbated by COVID-19-induced inflammation is the risk factor for COVID-19-associated rhino-orbito-cerebral mucormycosis: a matched pair case-control study. Indian J Ophthalmol. 2022;70:3096–101. https://doi.org/10.4103/ ijo.IJO_448_22
- Muthu V, Dhaliwal M, Sharma A, Nair D, Kumar HM, Rudramurthy SM, et al. Serum glucose-regulated protein 78 (GRP78) levels in COVID-19-associated mucormycosis: results of a case-control study. Mycopathologia. 2022; 187:355–62. https://doi.org/10.1007/s11046-022-00645-6
- Pandit AK, Tangri P, Misra S, Srivastava MVP, Bhatnagar S, Thakar A, et al. Mucormycosis in COVID-19 patients: a casecontrol study. Microorganisms. 2022;10:1209. https://doi. org/10.3390/microorganisms10061209
- Patel AK, Bakshi H, Shah K, Patel S, Patel T, Patel K, et al. Risk factors for COVID-19 associated mucormycosis in India: a case control study. Med Mycol. 2022;60:myac044. https://doi.org/10.1093/mmy/myac044
- Ponnaiah M, Ganesan S, Bhatnagar T, Thulasingam M, Majella MG, Karuppiah M, et al. Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: case-control study, India. PLoS One. 2022;17:e0272042. https://doi.org/10.1371/ journal.pone.0272042
- Popli H, Gupta A, Singh V, Agarwal V, Akilan R, Kumar A. Are low serum vitamin D levels a risk factor for advent of COVID-19 associated rhinocerebral mucormycosis: a preliminary case control study. Indian J Otolaryngol Head Neck Surg. 2022 Jan 11 [Epub ahead of print]. https://doi.org/ 10.1007/s12070-022-03080-7
- 35. Vasanthapuram VH, Gupta R, Adulkar N, Nair AG, Bradoo RA, Hegde R, et al. A fungal epidemic amidst a viral pandemic: risk factors for development of COVID-19 associated rhino-orbital-cerebral mucormycosis in India. Orbit. 2022 Feb 22 [Epub ahead of print]. https://doi.org/ 10.1080/01676830.2021.2020851
- Yesupatham ST, Mohiyuddin SMA, Arokiyaswamy S, Brindha HS, Anirudh PB. Estimation of Ferritin and D-Dimer levels in COVID-19 patients with mucormycosis: a crosssectional study. J Clin Diagn Res. 2022;16:BC12–5. https://doi.org/10.7860/JCDR/2022/52844.15908
- Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7:1127–40. https://doi.org/10.1038/ s41564-022-01172-2
- Mulakavalupil B, Vaity C, Joshi S, Misra A, Pandit RA. Absence of case of mucormycosis (March 2020–May 2021)

COVID-19-Associated Mucormycosis Outbreak, India

under strict protocol driven management care in a COVID-19 specific tertiary care intensive care unit. Diabetes Metab Syndr. 2021;15:102169. https://doi.org/10.1016/ j.dsx.2021.06.006

- Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Chen SC, et al. Contemporary management and clinical outcomes of mucormycosis: a systematic review and meta-analysis of case reports. Int J Antimicrob Agents. 2019;53:589–97. https://doi.org/10.1016/j.ijantimicag. 2019.01.002
- Muthu V, Agarwal R, Dhooria S, Sehgal IS, Prasad KT, Aggarwal AN, et al. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. Clin Microbiol Infect. 2021;27:538–49. https://doi.org/10.1016/j.cmi.2020.12.035
- Muthu V, Agarwal R, Chakrabarti A. COVID-19-associated pulmonary mucormycosis: an underdiagnosed entity with high mortality. Mycopathologia. 2022;187:405–6. https://doi.org/10.1007/s11046-022-00638-5
- 42. Pruthi H, Muthu V, Bhujade H, Sharma A, Baloji A, Ratnakara RG, et al. Pulmonary artery pseudoaneurysm in COVID-19-associated pulmonary mucormycosis: case series and systematic review of the literature. Mycopathologia. 2022;187:31–7. https://doi.org/10.1007/s11046-021-00610-9

Address for correspondence: Ritesh Agarwal, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Sector-12, Chandigarh 160012, India; email: agarwal.ritesh@outlook.in

Multicenter Case-Control Study of COVID-19–Associated Mucormycosis Outbreak, India

Appendix

Study Sites and Data Collection

The study was conducted after the Institute ethics committee of each study site approved the project. We circulated a standardized case-record form to the participating centers, and data was extracted manually from the individual patient case records by research personnel. We gathered anonymized patient data and ensured confidentiality. We assigned unique identification numbers for each form and entered them into a freely available mobilebased data gathering platform (Epicollect5). Data entry was done by trained clinical research staff at the coordinating center (Postgraduate Institute of Medical Education and Research [PGIMER], Chandigarh) under the supervision of four investigators (V.M., R.A., S.M.R., A.C.). Double entry of all the CAM cases was performed by two investigators (V.M. and R.A.). We imported the data to a spreadsheet before transferring it to statistical software for data analysis.

References

- Muthu V, Kumar M, Paul RA, Zohmangaihi D, Choudhary H, Rudramurthy SM, et al. Is there an association between zinc and COVID-19–associated mucormycosis? Results of an experimental and clinical study. Mycoses. 2021;64:1291–7. <u>PubMed</u> <u>https://doi.org/10.1111/myc.13365</u>
- 2. Bansal SB, Rana A, Babras M, Yadav D, Jha P, Jain M, et al. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients. Transpl Infect Dis. 2022;24:e13777. <u>PubMed https://doi.org/10.1111/tid.13777</u>
- 3. Arora U, Priyadarshi M, Katiyar V, Soneja M, Garg P, Gupta I, et al. Risk factors for coronavirus disease–associated mucormycosis. J Infect. 2022;84:383–90. <u>PubMed</u> <u>https://doi.org/10.1016/j.jinf.2021.12.039</u>

- 4. Karat S, Lobo AC, Satish D, Devaraj R, Manjooran RR, Nithyanandam S. Uncontrolled diabetes mellitus exacerbated by COVID-19–induced inflammation is the risk factor for COVID-19– associated rhino-orbito-cerebral mucormycosis: a matched pair case-control study. Indian J Ophthalmol. 2022;70:3096–101. <u>PubMed https://doi.org/10.4103/ijo.IJO_448_22</u>
- Kumar HM, Sharma P, Rudramurthy SM, Sehgal IS, Prasad KT, Pannu AK, et al. Serum iron indices in COVID-19-associated mucormycosis: a case-control study. Mycoses. 2022;65:120–7. <u>PubMed https://doi.org/10.1111/myc.13391</u>
- 6. Kumar S, Acharya S, Jain S, Shukla S, Talwar D, Shah D, et al. Role of zinc and clinicopathological factors for COVID-19–associated mucormycosis (CAM) in a rural hospital of central India: a case-control study. Cureus. 2022;14:e22528. <u>PubMed</u> <u>https://doi.org/10.7759/cureus.22528</u>
- 7. Muthu V, Dhaliwal M, Sharma A, Nair D, Kumar HM, Rudramurthy SM, et al. Serum glucoseregulated protein 78 (GRP78) levels in COVID-19-associated mucormycosis: results of a case-control study. Mycopathologia. 2022;187:355–62. <u>PubMed</u> <u>https://doi.org/10.1007/s11046-022-00645-6</u>
- Pandit AK, Tangri P, Misra S, Srivastava MVP, Bhatnagar S, Thakar A, et al. Mucormycosis in COVID-19 patients: a case-control study. Microorganisms. 2022;10:1209. <u>PubMed</u> <u>https://doi.org/10.3390/microorganisms10061209</u>
- 9. Patel AK, Bakshi H, Shah K, Patel S, Patel T, Patel K, et al. Risk factors for COVID-19 associated mucormycosis in India: a case control study. Med Mycol. 2022;60:myac044. <u>PubMed</u> <u>https://doi.org/10.1093/mmy/myac044</u>
- Ponnaiah M, Ganesan S, Bhatnagar T, Thulasingam M, Majella MG, Karuppiah M, et al. Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: case-control study, India. PLoS One. 2022;17:e0272042. <u>PubMed https://doi.org/10.1371/journal.pone.0272042</u>
- 11. Popli H, Gupta A, Singh V, Agarwal V, Akilan R, Kumar A. Are low serum vitamin D levels a risk factor for advent of COVID-19 associated rhinocerebral mucormycosis: a preliminary case control study. Indian J Otolaryngol Head Neck Surg. 2022 Jan 11 [Epub ahead of print]. PubMed https://doi.org/10.1007/s12070-022-03080-7
- 12. Vasanthapuram VH, Gupta R, Adulkar N, Nair AG, Bradoo RA, Hegde R, et al. A fungal epidemic amidst a viral pandemic: risk factors for development of COVID-19 associated rhino-orbital-cerebral mucormycosis in India. Orbit. 2022 Feb 22 [Epub ahead of print]. PubMed https://doi.org/10.1080/01676830.2021.2020851

Yesupatham ST, Mohiyuddin SMA, Arokiyaswamy S, Brindha HS, Anirudh PB. Estimation of Ferritin and D-Dimer levels in COVID-19 patients with mucormycosis: a cross-sectional study. J Clin Diagn Res. 2022;16:BC12–5. <u>https://doi.org/10.7860/JCDR/2022/52844.15908</u>

Appendix Table 1. Details of the participating center and the number (percentage) of COVID-19 controls and COVID-19associated mucormycosis (CAM) cases

Center		COVID-19		
no.	Participating center	controls	CAM	Mortality in CAM, n/N (%)
1	Postgraduate Institute of Medical Education and Research,	1084 (27.7)	327 (18.9)	114/250 (45.6)
	Chandigarh			
2	Kovai Medical Center, Coimbatore	425 (10.9)	86 (5.0)	20/73 (27.4)
3	Avron Hospitals, Ahmedabad	229 (5.9)	169 (9.8)	27/169 (16)
4	Sterling hospital, Ahmedabad	293 (7.5)	100 (5.8)	23/100 (23)
5	Sir Gangaram Hospital, New Delhi	254 (6.5)	123 (7.1)	28/123 (22.8)
6	Kingsway Hospital, Nagpur	185 (4.7)	97 (5.6)	12/92 (13)
7	Sawai Man Singh Medical College, Jaipur	100 (2.6)	119 (6.9)	15/49 (30.6)
8	Asian Institute of gastroenterology, Hyderabad	177 (4.5)	36 (2.1)	3/36 (8.3)
9	St. John's National Academy of Health Sciences, Bengaluru	146 (3.7)	64 (3.7)	30/45 (66.7)
10	Care Institute of Medical Sciences, Ahmedabad, Gujarat	132 (3.4)	66 (3.8)	11/66 (16.7)
11	All India Institute of Medical Sciences, Bhubaneshwar	124 (3.2)	42 (2.4)	10/42 (23.8)
12	Yashoda Hospital, Hyderabad	102 (2.6)	61 (3.5)	17/60 (28.3)
13	Royal Care Hospital, Coimbatore	113 (2.9)	30 (1.7)	13/29 (44.8)
14	Apollo Hospitals, Chennai	105 (2.7)	37 (2.1)	15/37 (40.5)
15	Government Medical College, Patiala	89 (2.3)	46 (2.7)	24/46 (52.2)
16	Poona Hospital Research center, Pune	71 (1.8)	32 (1.8)	8/32 (25)
17	Apollo Hospitals, Bengaluru	86 (2.2)	85 (4.9)	22/85 (25.9)
18	Kokilaben Hospital, Mumbai	50 (1.3)	25 (1.4)	3/25 (12)
19	Research and Referral (Army) hospital, Delhi	44 (1.1)	28 (1.6)	7/28 (25)
20	Government Medical College, Chandigarh	18 (0.5)	52 (3.0)	26/52 (50)
21	Global Hospital, Mumbai	33 (0.8)	33 (1.9)	0/32 (0)
22	Deenanath Mangeshkar Hospital, Pune	20 (0.5)	29 (1.7)	3/29 (10.3)
23	City clinic and Bhailal Amin General Hospital, Vadodara	31 (0.8)	14 (0.8)	7/14 (50)
24	All India Institute of Medical Sciences, New Delhi	0	17 (1.0)	3/17 (17.6)
25	Institute of Infectious Disease & Critical Care, Surat	0	15 (0.9)	1/15 (6.7)
	Total	3,911	1,733	442/1,546 (28.6)

Appendix Table 2. Details of the multiple imputations performed using the Markov Chain Monte Carlo method

Parameter	Туре	Missing Values	Imputed Values
Diabetic ketoacidosis at COVID-19 admission	Logistic Regression	108	5400
Mechanical ventilation for COVID-19	Logistic Regression	121	6050
Glucocorticoids for COVID-19	Logistic Regression	128	6400
Zinc supplementation for COVID-19	Logistic Regression	186	9300
Mortality at six weeks	Logistic Regression	186	9300
Appropriateness of glucocorticoids	Logistic Regression	243	12150
Mortality at twelve weeks	Logistic Regression	261	13050
Rural or urban	Logistic Regression	423	21150
Cumulative dose of glucocorticoids	Linear Regression	961	48050
Neutrophil-lymphocyte ratio	Linear Regression	1088	54400
C-reactive protein	Linear Regression	1175	58750
Serum ferritin	Linear Regression	1423	71150

Appendix Table 3. Multivariate logistic regression analysis showing factors associated with mucormycosis in COVID-19

(complete case analysis)		
Parameter	Adjusted Odds ratio (95% CI)	p-value
Female sex	1.03 (0.65–1.63)	0.89
Rural residence	2.61 (1.61-4.21)	0.0001
Risk factor		
No risk factor	Reference category	
Diabetes mellitus	2.63 (1.72-4.05)	0.0001
Renal transplantation	8.20 (2.10-32.03)	0.002
Others*	1.01 (0.28–3.62)	0.98
Presence of any comorbid illness	0.67 (0.39–1.11)	0.14
Hypoxia during COVID-19	0.58 (0.37-0.92)	0.02
Diabetic ketoacidosis during COVID-19	6.37 (1.87–21.72)	0.003
Cumulative dose of glucocorticoids for COVID-19†	1.005 (1.003-1.007)	0.0001
Zinc supplementation during COVID-19	4.96 (3.21–7.65)	0.0001
C-reactive protein at admission	1.001 (0.99–1.004)	0.42
Serum ferritin, µg/L	1.00 (1.00–1.00)	0.73
Neutrophil-to-lymphocyte ratio	1.01 (0.99–1.03)	0.07

*Includes malignancies, hematological malignancies, immunosuppressive therapy, HIV, and others. †In mg of dexamethasone equivalent

Appendix Table 4. Multivariate logistic regression analysis showing factors associated with mucormycosis in the subgroups of hypoxemic and non-hypoxemic COVID-19 controls

Adjusted Odds ratio (95% CI)		
Hypoxemic	Non-hypoxemic	
0.90 (0.72–1.12)	1.20 (0.86–1.68)	
2.48 (1.88–3.27)*	3.17 (2.03–4.97)*	
· · ·		
Ref.	Ref.	
6.13 (4.91–7.65)*	9.96 (7.16–13.86)*	
8.74 (3.37-22.65)*	5.84 (1.76–19.33)†	
1.35 (0.73–2.48)	1.18 (0.53–2.64)	
0.55 (0.44-0.68)*	0.48 (0.35-0.65)*	
3.74 (1.64–5.35)*	4.43 (0.93–21.04)	
1.00 (1.00–1.01)†	1.01 (1.00–1.01)*	
3.05 (2.42-3.85)*	1.80 (1.31–2.46)*	
1.00 (1.00–1.01)§	1.01 (1.00–1.01)†	
1.00 (1.00–1.00)	1.00 (1.00–1.00)	
0.98 (0.97–0.99)*	1.03 (1.01–1.05)†	
· · ·		
ssive therapy, HIV, and others.		
	Adjusted Odds Hypoxemic 0.90 (0.72–1.12) 2.48 (1.88–3.27)* Ref. 6.13 (4.91–7.65)* 8.74 (3.37–22.65)* 1.35 (0.73–2.48) 0.55 (0.44–0.68)* 3.74 (1.64–5.35)* 1.00 (1.00–1.01)† 3.05 (2.42–3.85)* 1.00 (1.00–1.01)§ 1.00 (1.00–1.00) 0.98 (0.97–0.99)* seive therapy, HIV, and others.	

Appendix Table 5. Multivariate logistic regression analysis showing factors associated with mucormycosis in the subgroups of COVID-19 controls with and without comorbidities*

	Adjusted Odds ratio (95% CI)		
Parameter	With any comorbid illness	No comorbid illness	
Female sex	0.95 (0.57–1.59)	0.91 (0.72–1.16)	
Rural residence	1.89 (1.02–3.48)†	3.31 (2.42–4.51)‡	
Risk factor			
No risk factor	Ref.	Ref.	
Diabetes mellitus	7.34 (4.13–13.07)‡	6.52 (5.20-8.18)‡	
Renal transplantation	10.0 (2.79–35.82)‡	6.02 (1.92–18.91)†	
Others§	0.87 (0.25-3.01)	1.18 (0.53-2.64)	
Hypoxemia during COVID-19	0.22 (0.13–0.36)‡	0.27 (0.21–0.34)‡	
Diabetic ketoacidosis during COVID-19	3.04 (0.86-10.80)	5.65 (2.02-15.77)†	
Cumulative dose of glucocorticoids	1.007 (1.003–1.011)‡	1.005 (1.003–1.007)‡	
Zinc supplementation during COVID-19	3.94 (2.38–6.54)‡	2.55 (2.01–3.23)‡	
C-reactive protein at admission	1.002 (0.99–1.01)	1.004 (1.002–1.007)‡	
Serum ferritin, µg/L	1.00 (1.00–1.00)	1.00 (1.00–1.00)	
Neutrophil-to-lymphocyte ratio	1.002 (0.99-1.02)	1.0 (0.99–1.01)	
*Comorbid illnesses included chronic liver disease, chronic kidney	disease, chronic heart failure, coronary ar	tery disease, and chronic respiratory	
disease.			
†p-value <0.05.			
<u>tp</u> value <0.0001.	reacive theremy LIN/ and others		

_§Includes malignancies, hematological malignancies, immunosuppressive therapy, HIV, and others

Appendix Table 6. Multivariate logistic regression analysis showing factors associated with mucormycosis in COVID-19 (alternative model where glucocorticoid dose has been replaced by inappropriate glucocorticoid use [glucocorticoid use in those without hypoxemia])

Parameter	Adjusted Odds ratio (95% CI)	P-value
Female sex	0.93 (0.77–1.12)	0.42
Rural residence	3.16 (2.48–4.02)	0.0001
Risk factor		
No risk factor	Ref.	
Diabetes mellitus	6.43 (5.38–7.69)	0.0001
Renal transplantation	8.61 (4.07–18.20)	0.0001
Others*	1.42 (0.82–2.47)	0.22
Presence of any comorbid illness	0.48 (0.39-0.60)	0.0001
Hypoxia during COVID-19	0.85 (0.66–1.08)	0.18
Diabetic ketoacidosis during COVID-19	3.09 (1.70-5.65)	0.0001
Use of glucocorticoids in the absence of hypoxemia	2.00 (1.37–2.94)	0.0001
Zinc supplementation during COVID-19	2.03 (1.71–2.43)	0.0001
C-reactive protein at admission	1.005 (1.003–1.007)	0.0001
Serum ferritin, μg/L	1.00 (1.00–1.00)	0.79
Neutrophil-to-lymphocyte ratio	1.00 (0.99–1.01)	0.85
** * * * * * * * * * * * * * * *		

*Includes malignancies, hematological malignancies, immunosuppressive therapy, HIV, and others.

Appendix Table 7. Logistic regression analysis showing factors associated with mortality at twelve weeks in subjects with COVID-19-associated mucormycosis (complete case analysis)

Parameter	Adjusted Odds ratio (95% CI)	P-value
Age	1.02 (1.01–1.04)	0.0001
Sex	1.02 (0.76–1.37)	0.92
Risk factor		
No risk factor	Ref.	
Diabetes mellitus	1.30 (0.93–1.82)	0.13
Renal transplantation	2.74 (1.11–6.83)	0.03
Others*	1.31 (0.46–3.76)	0.62
Presence of any comorbid illness	1.34 (0.95–1.88)	0.09
Hypoxemia during COVID-19 illness	1.34 (1.04–1.73)	0.03
Site of involvement by mucormycosis		
Rhino-orbital mucormycosis (ROM)	Ref.	
ROM with brain involvement	2.80 (1.99–3.93)	0.0001
Other sites†	1.51 (0.92–2.46)	0.10
Primary combination medical therapy	0.49 (0.37–0.63)	0.0001
Combined medical and surgical treatment	0.15 (0.10-0.21)	0.0001

*Includes hematological malignancies, immunosuppressive therapy, and HIV infection. †Includes pulmonary, gastrointestinal, disseminated, and renal mucormycosis.

Reference	Country	CAM	COVID-19	Exposure assessed	Key findings	Remarks
		(n)	controls (n)			
Muthu/2021 (<i>1</i>)	Chandigarh , India	28	29	Zinc	Univariate analysis showed diabetes mellitus was higher in the cases than in the controls. Zinc levels were similar in cases and controls, measured at different time points in cases and controls.	Small sample size, Limited factors assessed. Increased in-vitro growth of <i>Rhizpus arrhizus</i> isolates from CAM in zinc-enriched fungal culture medium
Bansal/2022 (2)	Gurugram, India	11	50	Demography, HbA1c, serum creatinine, lymphocyte count, D-dimer, ferritin, treatment of acute COVID-19, severity of COVID-19	Univariate analysis suggested higher HbA1c, nadir lymphocyte count, D- dimer, and ferritin in cases than controls	Small sample, included only kidney transplant recipients
Arora/2022 (3)	New Delhi, India	152	200	Diabetes mellitus, glucocorticoids, COVID-19 severity, hyperglycemia, nasopharyngeal swabs, zinc therapy, masks	Diabetes mellitus, glucocorticoids, hyperglycemia, a higher number of nasal swabs, and cloth mask usage were predictors on CAM on multivariate analysis	Single center, small sample size
Karat/2022 (4)	Bengaluru, India	69	138	Demography, diabetes mellitus, renal function tests, serum ferritin, COVID-19 severity indicators	Random blood sugar, glycated hemoglobin, and elevated C-reactive protein associated with CAM on multivariate analysis	Small sample size, limited factors assessed. Age and sex-matched controls
Kumar/2022 (5)	Chandigarh , India	28	26	Diabetes mellitus, glucocorticoids, serum iron, TIBC, serum ferritin	Diabetes mellitus and lower TIBC were predictors of CAM on multivariate analysis	Small sample size, limited factors assessed
Kumar/2022 (6)	Wardha, India	55	50	Demography, COVID-19 severity, glucocorticoid, and zinc therapy, diabetes mellitus, complete blood count, renal and liver function tests,	On univariate analysis higher proportion of CAM cases had zinc use	Small sample size, single center, limited factors assessed, unadjusted analysis
Muthu/2022 (7)	Chandigarh , India	24	24	Diabetes mellitus, COVID-19 hypoxemia, serum GRP-78 levels	Serum GRP78 levels were significantly higher in CAM than in COVID-19 controls (after adjusting for diabetes and hypoxia) on multivariate analysis	Small sample size, single- center, limited factors assessed
Pandit/2022 (8)	New Delhi, India	61	60	Demography, diabetes mellitus, alcohol, smoking, zinc, glucocorticoids, COVID- 19 admission parameters	Baseline serum creatinine and d- dimer associated independently with CAM on multivariate analysis	Small sample size, single- center, limited factors assessed
Patel/2022 (9)	Ahmedabad , India	64	205	Demography, Diabetes, COVID-19 hypoxia, hospitalization, laboratory, and treatment parameters	Diabetes mellitus, new-onset diabetes, glucocorticoid therapy, home isolation on multivariate analysis	Small sample size, single- center
Ponniah/2022 (10)	India; multicenter	383	487	Demography, housing details, occupation, comorbid illness, COVID-19 severity, and treatment. Details of mask and nasal wash during COIVD-19 illness	Hospitalized COVID-19 patients with CAM were associated with diabetes mellitus, glucocorticoid use, and frequent nasal wash on multivariate analysis Non-hospitalized COVID-19 developing CAM were associated with diabetes mellitus, elevated	Separate analysis for hospitalized and non- hospitalized COVID-19 subjects

Appendix Table 8. Summary of the case-control studies assessing factors associated with mucormycosis in COVID-19

					plasma glucose, use of cloth mask,	
Popli/2022 (11)	Rohtak, India	23	23	Vitamin D	Univariate analysis suggested lower vitamin D in cases than in controls	Time of blood collection in cases vs. controls is not clearly mentioned
Vasanthapuram/2022 (12)	India; multicenter	179	361	Male sex, diabetes mellitus, glucocorticoid therapy for covid-19, hypoxemia, anti-IL6	Male sex, diabetes mellitus, glucocorticoid therapy for covid-19, and hypoxemia were predictors of CAM on multivariate analysis	Only ROCM, limited factors assessed
Yesupatham/2022 (13)	Kolar, India	40	44	D-dimer, ferritin	Univariate analysis suggested higher D-dimer and ferritin in cases than in the controls	Time of blood collection in cases vs. controls is not clearly mentioned

*CAM, COVID-19-associated mucormycosis; GRP-78, 78 kg-Dalton glucose-regulated protein; HbA1c, glycated hemoglobin; ROCM, rhino-orbito-cerebral mucormycosis; TIBC, total iron binding capacity.



Appendix Figure. Representative map showing the distribution of the various participating centers (numbered 1–25) in multicenter case-control study of COVID-19–associated mucormycosis outbreak, India, January–June 2021